```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 19:03:28 ON 16 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 16 Sep 2009  VOL 151 ISS 12
FILE LAST UPDATED: 15 Sep 2009  (20090915/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information.  This enhancement may impact record import into
database management software.  For additional information, refer
to NEWS 9.

=>
=> d stat que l21
L1              STR
```




```
VAR G1=CH/10
NODE ATTRIBUTES:
NSPEC   IS RC     AT   8
NSPEC   IS RC     AT   9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
```

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L3 9002 SEA FILE=REGISTRY SSS FUL L1
L14 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L15 4 SEA FILE=REGISTRY SUB=L3 SSS FUL L14
L16 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L17 1 SEA FILE=REGISTRY SUB=L3 SSS FUL L16
L18 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L15
L19 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L17
L20 322253 SEA FILE=HCAPLUS ABB=ON PLU=ON "ANTIMICROBIAL AGENTS"/CV OR ANTIMICROB? OR DISINFECT? OR ANTISEPT? OR ANTIBACT? OR BACTERICID? OR BACTERIOSTAT? OR ("ANTIBACTERIAL AGENTS"/CV OR "ANTIBACTERIAL AGENTS (L) SYNERGISTIC"/CV OR "ANTIBACTERIOPHAGIC ACTION"/CV OR ANTISEPTICS/CV OR "BACTERICIDAL ACTION"/CV OR "BACTERICIDAL ACTION (L) SYNERGISTIC"/CV OR "BACTERICIDAL ACTION AND BACTERIOSTATIC ACTION"/CV OR "BACTERICIDAL ACTION OR BACTERIOSTATIC ACTION"/CV OR BACTERICIDES/CV OR "BACTERICIDES, DISINFECTANTS AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "BACTERICIDES, DISINFECTANTS, AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS, AND ANTISEPTICS (L) SYNERGISTIC"/CV OR BACTERIOSTASIS/CV OR "DISINFECTANTS AND ANTISEPTICS"/CV OR "DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "MICROBICIDAL AND

```
                MICROBIOSTATIC ACTION (L) BACTERIOSTATIC"/CV OR SPIROCHETICIDES
                /CV) OR GERMICID?
L21           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L18 OR L19) AND L20


=> d ibib abs hitstr l21 1-3

L21  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:        2008:505083  HCAPLUS  Full-text
DOCUMENT NUMBER:         148:464819
TITLE:                   Acaricidal thermoplastic resins and articles made
                         therefrom
INVENTOR(S):             Schneider, Armin; Herbst, Heinz; Rieffel, Thi Thoa;
                         Kolb, Markus
PATENT ASSIGNEE(S):      Ciba Holding Inc., Switz.
SOURCE:                  PCT Int. Appl., 35 pp.
                         CODEN: PIXXD2
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2008046746         A2    20080424    WO 2007-EP60576         20071005
     WO 2008046746         A3    20090723
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                       EP 2006-122323      A  20061016
OTHER SOURCE(S):         MARPAT 148:464819
AB    Synthetic thermoplastic polymer articles are effectively protected from
      infestation by mites, such as house dust mites or bed mites, by incorporation
      of an agent selected from propiconazole, cyproconazole, difenoconazole,
      fludioxonil, thiabendazole, tebuconazole, zinc pyrithione, 2-n-octyl-4-
      isothiazolin-3-one, 4,5-dichloro-N-n-octylisothiazolin-3-one, certain 2,4-
      bis(alkylamino)pyrimidines or silver compds., carbendazim, 10,10'-oxy-bis-
      phenoxyarsene, and/or n-butyl-1,2-benzisothiazolin-3-one and optionally an
      antimicrobial agent into the bulk of the resin.  The final articles may be
      filters, bed clothes and fillings, mattresses, covers, pillowcases, upholstery
      fabrics and foams, textiles, and floor coverings including carpets, backing
      material like backing for flooring, and underlays.  Thus, 0.2% triclosan and
      0.2% thiabendazole were mixed with polypropylene pellets (Moplen HP 451N) at
      room temperature and extruded via a twin-screw extruder at 230°, cooled,
      solidified, and used to produce polypropylene multifilament fibers with a
      fiber spinning line. The fibers were knitted into socks that, when soiled with
      natural dust, acclimated, and inoculated with mites (Dermatophagoides
      pteronyssinus) had no living dust mites after 6 wk of incubation under optimal
      conditions.
```

IT 838902-57-1
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(acaricidal thermoplastic resins and textiles and other articles made therefrom)
RN 838902-57-1 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-5-hexyl-6-methyl-N2-octyl- (CA INDEX NAME)



L21 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:438571 HCAPLUS Full-text
DOCUMENT NUMBER: 146:442660
TITLE: Thermoplastic material having antibacterial and antifungal properties for garments or footwear
INVENTOR(S): Herbst, Heinz
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 38pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2007042416	A1	20070419	WO 2006-EP66947		20061002
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
EP 1934277	A1	20080625	EP 2006-793939		20061002
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
JP 2009513837	T	20090402	JP 2008-534982		20061002
MX 2008004718	A	20080422	MX 2008-4718		20080410
IN 2008CN01799	A	20081226	IN 2008-CN1799		20080410
CN 101291982	A	20081022	CN 2006-80037920		20080411
KR 2008056756	A	20080623	KR 2008-710695		20080502
PRIORITY APPLN. INFO.:			EP 2005-109468	A	20051012
			WO 2006-EP66947	W	20061002

OTHER SOURCE(S): MARPAT 146:442660

AB A garment or footwear is based on a synthetic thermoplastic polymer material containing (a) an antibacterial agent selected from phenolic antimicrobial compds. (e.g., 2,4,4'-trichloro-2'-hydroxy-diphenyl ether); and (b) an antifungal agent selected from benzimidazole fungicides, triazoles, 2,4-bis(alkylamino)pyrimidines, isothiazolinone fungicides, 10,10'-oxy-bis-phenoxyarsene, and zinc pyrithione.

IT 838902-57-1

RL: MOA (Modifier or additive use); USES (Uses)
(antifungal; thermoplastic material having antibacterial and antifungal properties for garments or footwear)

RN 838902-57-1 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-5-hexyl-6-methyl-N2-octyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:120774 HCAPLUS Full-text

DOCUMENT NUMBER: 142:194227

TITLE: Synthesis of 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials

INVENTOR(S): Marquais-Bienewald, Sophie; Hoelzl, Werner; Preuss, Andrea; Mehlin, Andreas

PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.

SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011758	A2	20050210	WO 2004-EP51516	20040716
WO 2005011758	A3	20050428		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

EP 1648524	A2	20060426	EP 2004-766240		20040716
EP 1648524	B1	20090114			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1829538	A	20060906	CN 2004-80021631		20040716
CN 100441228	C	20081210			
BR 2004012915	A	20060926	BR 2004-12915		20040716
JP 2007500683	T	20070118	JP 2006-521569		20040716
AT 420667	T	20090115	AT 2004-766240		20040716
ES 2320772	T3	20090528	ES 2004-766240		20040716
KR 2006052806	A	20060519	KR 2006-700734		20060111
MX 2006000771	A	20060418	MX 2006-771		20060120
US 20060188453	A1	20060824	US 2006-565545		20060123
IN 2006CN00279	A	20070706	IN 2006-CN279		20060123
PRIORITY APPLN. INFO.:			EP 2003-102296	A	20030725
			WO 2004-EP51516	W	20040716

OTHER SOURCE(S): MARPAT 142:194227

AB Provided are various 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials. The synthesized compds. were demonstrated to have antimicrobial activity against bacteria such as Staphylococcus aureus and Escherichia coli as well as fungi such as Candida albicans and Aspregillus niger. The intended use of these 2,4-bis(alkylamino)pyrimidines are as biocides or preservatives in numerous products such as paints, textiles, and plastics. Some of the compds. may also find use in cosmetic formulations or in mouthwashes.

IT 838902-98-0 838903-26-7

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(synthesis of 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials)

RN 838902-98-0 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-(diethylamino)propyl]-5-hexyl-6-methyl-N2-octyl- (CA INDEX NAME)



RN 838903-26-7 HCAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-[(3-aminopropyl)methylamino]propyl]-5-hexyl-6-methyl-N2-octyl- (CA INDEX NAME)



IT 838902-57-1P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of 2,4-bis(alkylamino)pyrimidines and their use as antimicrobials)
RN 838902-57-1 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-5-hexyl-6-methyl-N2-octyl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => d stat que l24
L1 STR



VAR G1=CH/10
NODE ATTRIBUTES:
NSPEC IS RC AT 8
NSPEC IS RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L3 9002 SEA FILE=REGISTRY SSS FUL L1
L6 STR



NODE ATTRIBUTES:
NSPEC IS C AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L7 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L8 STR



REP G1=(0-19) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L9 STR



REP G1=(0-19) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L10 STR



VAR G1=11/16/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L11 STR



VAR G1=11/16/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L13 4967 SEA FILE=REGISTRY SUB=L3 SSS FUL L6 OR L7 OR L8 OR L9 OR L10 OR L11
L14 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L15 4 SEA FILE=REGISTRY SUB=L3 SSS FUL L14
L16 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L17 1 SEA FILE=REGISTRY SUB=L3 SSS FUL L16
L18 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L15
L19 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L17
L20 322253 SEA FILE=HCAPLUS ABB=ON PLU=ON "ANTIMICROBIAL AGENTS"/CV OR ANTIMICROB? OR DISINFECT? OR ANTISEPT? OR ANTIBACT? OR BACTERICID? OR BACTERIOSTAT? OR ("ANTIBACTERIAL AGENTS"/CV OR "ANTIBACTERIAL AGENTS (L) SYNERGISTIC"/CV OR "ANTIBACTERIOPHAGIC ACTION"/CV OR ANTISEPTICS/CV OR "BACTERICIDAL ACTION"/CV OR "BACTERICIDAL ACTION (L) SYNERGISTIC"/CV OR "BACTERICIDAL ACTION AND BACTERIOSTATIC ACTION"/CV OR "BACTERICIDAL ACTION OR BACTERIOSTATIC ACTION"/CV OR BACTERICIDES/CV OR "BACTERICIDES, DISINFECTANTS AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "BACTERICIDES, DISINFECTANTS, AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS, AND ANTISEPTICS (L) SYNERGISTIC"/CV OR BACTERIOSTASIS/CV OR "DISINFECTANTS AND ANTISEPTICS"/CV OR "DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "MICROBICIDAL AND

```
                MICROBIOSTATIC ACTION (L) BACTERIOSTATIC"/CV OR SPIROCHETICIDES
                /CV) OR GERMICID?
L21           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L18 OR L19) AND L20
L22         738 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13
L23          23 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L22(L)L20
L24          21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23 NOT L21


=> d ibib abs hitstr l24 1-21

L24  ANSWER 1 OF 21  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:239535  HCAPLUS  Full-text
DOCUMENT NUMBER:          150:260214
TITLE:                    Preparation of arylpropargylicdiaminopyrimidine
                          derivatives as inhibitors of dihydrofolate reductase
                          with antibacterial, antiprotozoal, antifungal and
                          anticancer properties
INVENTOR(S):              Anderson, Amy C.; Wright, Dennis L.; Pelphrey, Phillip
                          M.; Joska, Tammy M.; Bolstad, Erin S. D.; Bolstad,
                          David B.; Popov, Veljko
PATENT ASSIGNEE(S):       University of Connecticut, USA
SOURCE:                   PCT Int. Appl., 103pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2009025919         A2    20090226    WO 2008-US65786         20080604
     WO 2009025919         A3    20090618
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
     US 20090105287        A1    20090423    US 2008-133099          20080604
PRIORITY APPLN. INFO.:                     US 2007-941828P      P  20070604
OTHER SOURCE(S):          MARPAT 150:260214
GI
```



I



II

AB Title compds. I [R = H, alkyl, alkoxy, and OH; R1-4 independently = H, alkyl, cycloalkyl, arylalkyl, etc.; A and B independently = H, halo, OH, haloalkyl, etc.; or A and B (un)substituted carbocycle; V, W, X, Y, and Z independently = H, halo, NO2, alkyl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of dihydrofolate reductase (DHFR). Thus, e.g., II was prepared via coupling of 2-bromo-5-methoxyacetophenone (preparation given) with phenylboronic acid, followed by homologation of the acetyl moiety via a Wittig reaction, hydrolysis to the aldehyde moiety, and condensation with Ohira-Bestmann reagent to form terminal acetylene which is coupled with 2,4-diamino-5-iodo-6-methylpyrimidine. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. A biphenyl derivative of I proved to be the most potent (1.1 nM) and most selective (1273-fold) of all compds. tested against Cryptosporidium DHFR enzyme. These compds. and other similar compds. are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

IT 223672-28-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylpropargylicdiaminopyrimidine derivs. as inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties)

RN 223672-28-4 HCAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



L24 ANSWER 2 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:137529 HCAPLUS Full-text
DOCUMENT NUMBER: 144:165787
TITLE: Agent with antibacterial activity
INVENTOR(S): Zielinski, Wojciech; Mazik, Monika; Klimach, Anna; Szybinska, Aleksandra; Ziminska, Zofia
PATENT ASSIGNEE(S): Politechnika Slaska Im Wincent, Pol.; Inst Przemyslu Organiczego
SOURCE: Pol., 6 pp.
CODEN: POXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Polish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 189237	B1	20050729	PL 1998-325444	19980318
PRIORITY APPLN. INFO.:			PL 1998-325444	19980318

OTHER SOURCE(S): MARPAT 144:165787
GI



I

AB Twenty agents based on structure (I), where R1 can be alkyl, amino or dialkylamino groups, R2 can be amino or dialkylamino groups, and R3 can be H, alkyl or Ph groups, are described. The compds. can be also substituted with Cl, nitro, methoxy or alkyl groups in different positions of the cycle. The compds. were prepared by reactions of aliphatic ketones or β-Ph α/β-unsatd. ketones with cyanamide or dialkylcyanamides directly or after conversion into oximes by phosphoric trichloride or PCl5. The m.ps. and MS ions M+ were determined The antibacterial activities were determined with test strains of Erwinia amylovora, E. carotovora phaseolicola atroseptica, Pseudomonas lachrymans, P. syringae, and P. phaseolicola. The antibacterial effectiveness of some agents was tested on beans with leaves infected with Pseudomonas phaseolicola.

IT 1791-73-7P 7471-62-7P
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrimidine derivs. with antibacterial activity)

RN 1791-73-7 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl- (CA INDEX NAME)



RN 7471-62-7 HCAPLUS
CN 2,4-Pyrimidinediamine, N2,N2,N4,N4,6-pentamethyl- (CA INDEX NAME)



L24 ANSWER 3 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:239939 HCAPLUS Full-text
DOCUMENT NUMBER: 144:36305
TITLE: Synthesis and antimicrobial activity of 2-(2'-substituted hydrazono)-1,3-dithiacyclopentane derivatives
AUTHOR(S): Zhu, Xiao-Kang; Chen, Hong-Chao; Wang, Yu-Liang; Gou, Shao-Hua; Jiang, Man; Yang, Zhi-Rong; Xiang, Ming
CORPORATE SOURCE: Faculty of Chemistry, Sichuan University, Chengdu, 610064, Peop. Rep. China
SOURCE: Youji Huaxue (2005), 25(3), 327-331
CODEN: YCHHDX; ISSN: 0253-2786
PUBLISHER: Kexue Chubanshe
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
OTHER SOURCE(S): CASREACT 144:36305
AB Eleven 2-(2'-substituted hydrazono)-1,3-dithiacyclopentane derivs. have been designed and synthesized. Their structures have been confirmed by 1H NMR, MS, IR spectra and elemental anal. The antimicrobial test showed that the compds. possess a good antimicrobial activity on the testing bacterium and more expansive antimicrobial activity than tricyclazole and thiophanate-Me. Among these, 2-(p-fluorophenoxyacetylhydrazono)-1,3- dithiacyclopentane has good antimicrobial activity against S. aureus, E. coli, S. ligneres, P. Vulgaris and D. cata.
IT 266346-28-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antimicrobial activity of 2-(2'-substituted hydrazono)-1,3-dithiacyclopentane derivs.)
RN 266346-28-5 HCAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 6-methyl-, bis(1,3-dithiolan-2-ylidenehydrazone) (9CI) (CA INDEX NAME)



IT 1980-55-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis and antimicrobial activity of 2-(2'-substituted hydrazono)-1,3-dithiacyclopentane derivs.)
RN 1980-55-8 HCAPLUS
CN Pyrimidine, 2,4-dihydrazinyl-6-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 4 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:58230 HCAPLUS Full-text
DOCUMENT NUMBER: 142:155967
TITLE: Preparation of heteroarylhydrazinocarbonylcarbocycles as peptide deformylase (PDF) inhibitors useful as antibacterials
INVENTOR(S): Aubart, Kelly M.; Christensen, Siegfried Benjamin, IV; Duraiswami, Chaya; Karpinski, Joseph M.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005005456	A2	20050120	WO 2004-US22067	20040708
WO 2005005456	A3	20050324		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20060160802	A1	20060720	US 2006-563777		20060106
US 7332485	B2	20080219			
PRIORITY APPLN. INFO.:			US 2003-485510P	P	20030708
			WO 2004-US22067	W	20040708

OTHER SOURCE(S): CASREACT 142:155967; MARPAT 142:155967

AB RXNHYNHCOACH2N(OH)CHO [A = (substituted) 3-8 membered 1,1-carbocyclylene; Y = bond, or Y = bond, CH2 when X = CO; X = bond, CH2, CO; R = aryl, heteroaryl], were prepared as PDF inhibitors useful as antibacterials (no data). Thus, cis-1-[(benzyloxyformylamino)methyl]-4- methylcyclohexanecarboxylic acid (preparation given) and 2-hydrazino-4-trifluoromethylpyrimidine were stirred with NMM, HOAt, and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride in DMF to give 70% N-benzyloxy-N-[cis-4-methyl-1-[N'-(4-trifluoromethylpyrimidin-2- yl)hydrazinocarbonyl]cyclohexylmethyl]formamide. This was hydrogenolyzed in MeOH over Pd/C for 4 h at room temperature to give 86% N-hydroxy-N-[cis-4-methyl-1-[N'-(4-trifluoromethylpyrimidin-2-yl)hydrazinocarbonyl]cyclohexylmethyl]formamide.

IT 828270-83-3P 828270-92-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of heteroarylhydrazinocarbonylcarbocycles as peptide deformylase (PDF) inhibitors useful as antibacterials)

RN 828270-83-3 HCAPLUS

CN Cyclohexanecarboxylic acid, 1-[(formylhydroxyamino)methyl]-4,4-dimethyl-, 2-[4-methyl-6-(4-morpholinyl)-2-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 828270-92-4 HCAPLUS

CN Cycloheptanecarboxylic acid, 1-[(formylhydroxyamino)methyl]-, 2-[4-methyl-6-(4-morpholinyl)-2-pyrimidinyl]hydrazide (CA INDEX NAME)



IT 828271-73-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylhydrazinocarbonylcarbocycles as peptide deformylase (PDF) inhibitors useful as antibacterials)
RN 828271-73-4 HCAPLUS
CN Cyclohexanecarboxylic acid, 1-[(formylhydroxyamino)methyl]-4-methyl-, 2-[4-methyl-6-(4-morpholinyl)-2-pyrimidinyl]hydrazide, cis- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:568194 HCAPLUS Full-text
DOCUMENT NUMBER: 141:123651
TITLE: Preparation of 6-methyl-2,4-diamino-pyrimidines by amination, their cosmetic and pharmaceutical, in particular dermatological, compositions containing them and their uses as basic neutralizing agents, and antimicrobial agents, in particular antibacterial and antifungal agents
INVENTOR(S): Breton, Philippe; Dalko, Maria; Forestier, Serge; Buiatti, Muriel; Lerebour, Geraldine
PATENT ASSIGNEE(S): L'oreal, Fr.
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1437348	A1	20040714	EP 2003-293239	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
WO 2006016014	A1	20060216	WO 2004-FR1847	20040713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI,
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS,
MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM

PRIORITY APPLN. INFO.: FR 2003-300 A 20030113
FR 2003-10918 A 20030917

OTHER SOURCE(S): CASREACT 141:123651; MARPAT 141:123651

GI



I



II

AB Title compds. I [wherein R1, R2 = independently (un)substituted (un)saturated linear or branched hydrocarbyl, NR1R2 = (un)substituted nonarom. heterocycle, when R1 = H, R2 is not H; and vice versa] were prepared as basic neutralizing agents, and antimicrobial agents, in particular antibacterial and antifungal agents, for use in cosmetic and pharmaceutical. Nine formulations are given. For example, II was prepared by amination of 2-amino-4-chloro-6-methylpyrimidine with n-hexylamine in EtOH in the presence of DIPEA at reflux for 24 h. I displayed pKa values > 7.5, demonstrating their action as basic neutralizing agents. The antimicrobial activity was evaluated against 2 Gram-neg. bacteria - E. coli and P. aeruginosa, one Gram-pos. bacteria - S.aureus and C. albicans. I gave min. inhibitory concentration (MIC) values against E. coli in the range of 0.078 - 5 mg/mL. I are useful in cosmetic and pharmaceutical, in particular dermatol., compns.

IT 1791-73-7DP, 6-Methylpyrimidine-2,4-diamine, derivs.
91717-22-5P, 2-Amino-4-methyl-6-(piperidin-1-yl)pyrimidine
494778-46-0P, 2-Amino-4-[(n-Hexyl)amino]-6-methylpyrimidine
723508-60-9P, 4-[(2-Amino-6-methylpyrimidin-4-yl)amino]butyldimethylsilanol 723508-72-3P, 2-Amino-6-methyl-4-[(piperidin-1-yl)amino]pyrimidine
723508-79-0P, 2-Amino-4-[[4-(methoxydimethylsilyl)butyl]amino]-6-methylpyrimidine 723508-86-9P, 2-Amino-4-[(4-piperidinylmethyl)amino]-6-methylpyrimidine
723508-93-8P, 2-Amino-4-[[((2S)-2-pyrrolidinyl)methyl]amino]-6-methylpyrimidine 723508-99-4P, 2-Amino-4-[(2-amino-2-methylpropyl)amino]-6-methylpyrimidine
723509-06-6P, 2-Amino-6-methyl-4-[[2-(piperazin-1-

yl)ethyl]amino]pyrimidine 723509-12-4P,
2-Amino-6-methyl-4-[[(5-methylfuran-2-yl)methyl]amino]pyrimidine
723509-19-1P, 2-Amino-4-[[[3-(aminomethyl)cyclohexyl]methyl]amino]-
6-methylpyrimidine 723509-54-4P,
2-(2-Amino-6-methylpyrimidin-4-yl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol
723509-83-9P, 2-Amino-4-[[3-(ethoxydimethylsilyl)propyl]amino]-6-
methylpyrimidine 723509-90-8P,
2-Amino-4-[[3-(ethoxydiisopropylsilyl)propyl]amino]-6-methylpyrimidine
723509-97-5P, 2-Amino-4-[[(1-ethylpyrrolidin-2-yl)methyl]amino]-6-
methylpyrimidine 723511-06-6P,
2-Amino-4-[(Furan-2-ylmethyl)amino]-6-methylpyrimidine
723511-15-7P, [4-Methyl-6-(pyrrolidin-1-yl)pyrimidin-2-yl]amine
723511-20-4P, 1-(2-Amino-6-methylpyrimidin-4-yl)pyrrolidin-3-ol
723511-27-1P, [1-(2-Amino-6-methylpyrimidin-4-yl)pyrrolidin-3-
yl]methanol 723511-33-9P,
[4-Methyl-6-(2-methylpyrrolidin-1-yl)pyrimidin-2-yl]amine
723511-39-5P, [4-(2-Isopropylpyrrolidin-1-yl)-6-methylpyrimidin-2-
yl]amine 723511-45-3P,
1-(2-Amino-6-methylpyrimidin-4-yl)pyrrolidine-2-carbonitrile
723511-51-1P, [4-Methyl-6-(3-phenylpyrrolidin-1-yl)pyrimidin-2-
yl]amine 723511-58-8P,
[4-Methyl-6-[3-(pyridin-3-yl)pyrrolidin-1-yl]pyrimidin-2-yl]amine
723511-63-5P, [4-Methyl-6-[3-(pyridin-2-yl)pyrrolidin-1-
yl]pyrimidin-2-yl]amine
RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(antimicrobial agent; preparation of 6-Me-2,4-diamino-pyrimidines
by amination as basic neutralizing agents, and antimicrobial
agents, in particular antibacterial and antifungal, and their
use in cosmetic and pharmaceutical compns.)

RN 1791-73-7 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl- (CA INDEX NAME)



RN 91717-22-5 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-(1-piperidinyl)- (CA INDEX NAME)



RN 494778-46-0 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-hexyl-6-methyl- (CA INDEX NAME)



RN 723508-60-9 HCAPLUS
CN Silanol, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]butyl]-1,1-dimethyl- (CA INDEX NAME)



RN 723508-72-3 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-1-piperidinyl- (CA INDEX NAME)



RN 723508-79-0 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(methoxydimethylsilyl)butyl]-6-methyl- (CA INDEX NAME)



RN 723508-86-9 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 723508-93-8 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[(2S)-2-pyrrolidinylmethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 723508-99-4 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(2-amino-2-methylpropyl)-6-methyl- (CA INDEX NAME)



RN 723509-06-6 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[2-(1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 723509-12-4 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)



RN 723509-19-1 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[[3-(aminomethyl)cyclohexyl]methyl]-6-methyl- (CA INDEX NAME)



RN 723509-54-4 HCAPLUS
CN 6,7-Isoquinolinediol, 2-(2-amino-6-methyl-4-pyrimidinyl)-1,2,3,4-tetrahydro- (CA INDEX NAME)



RN 723509-83-9 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-(ethoxydimethylsilyl)propyl]-6-methyl- (CA INDEX NAME)



RN 723509-90-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[3-[ethoxybis(1-methylethyl)silyl]propyl]-6-methyl- (CA INDEX NAME)



RN 723509-97-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methyl- (CA INDEX NAME)



RN 723511-06-6 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(2-furanylmethyl)-6-methyl- (CA INDEX NAME)



RN 723511-15-7 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-(1-pyrrolidinyl)- (CA INDEX NAME)



RN 723511-20-4 HCAPLUS
CN 3-Pyrrolidinol, 1-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 723511-27-1 HCAPLUS
CN 3-Pyrrolidinemethanol, 1-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 723511-33-9 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-(2-methyl-1-pyrrolidinyl)- (CA INDEX NAME)



RN 723511-39-5 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-[2-(1-methylethyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 723511-45-3 HCAPLUS
CN 2-Pyrrolidinecarbonitrile, 1-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 723511-51-1 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-(3-phenyl-1-pyrrolidinyl)- (CA INDEX NAME)



RN 723511-58-8 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-[3-(3-pyridinyl)-1-pyrrolidinyl]- (CA INDEX NAME)



RN 723511-63-5 HCAPLUS
CN 2-Pyrimidinamine, 4-methyl-6-[3-(2-pyridinyl)-1-pyrrolidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:971879 HCAPLUS Full-text
DOCUMENT NUMBER: 140:41828
TITLE: Preparation of N-hydroxy-N-(3-hydrazino-3-oxopropyl)formamide derivatives as peptide deformylase inhibitors with antibacterial activity
INVENTOR(S): Aubart, Kelly M.; Benowitz, Andrew B.; Christensen, Siegfried B., IV; Karpinski, Joseph M.; Lee, Jinhwa; Silva, Domingos J.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101442	A1	20031211	WO 2003-US17054	20030530
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV,				

MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2487805	A1	20031211	CA 2003-2487805		20030530
AU 2003247445	A1	20031219	AU 2003-247445		20030530
AU 2003247445	B2	20090226			
BR 2003011318	A	20050222	BR 2003-11318		20030530
EP 1509218	A1	20050302	EP 2003-756286		20030530
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006501155	T	20060112	JP 2004-508800		20030530
NZ 536103	A	20070928	NZ 2003-536103		20030530
AP 1795	A	20071231	AP 2004-3156		20030530
ZA 2004008315	A	20061227	ZA 2004-8315		20041014
IN 2004DN03241	A	20050401	IN 2004-DN3241		20041020
US 20050222412	A1	20051006	US 2004-512926		20041029
MX 2004011951	A	20050331	MX 2004-11951		20041130
NO 2004005675	A	20041228	NO 2004-5675		20041228
PRIORITY APPLN. INFO.:			US 2002-384457P	P	20020531
			WO 2003-US17054	W	20030530

OTHER SOURCE(S): MARPAT 140:41828

AB Title N-hydroxyformamide derivs. R1R2NNHCOCH(Y-R)CH2N(OH)CHO [R is (un)substituted alk(en)(yn)yl, carbocyclyl, carbocyclylmethyl, carbocyclylethyl, (hetero)aryl, or heterocyclyl ; Y is O, CH2 or a covalent bond; R1, R2 are H or groups given for R] or their salts were prepared as peptide deformylase (PDF) inhibitors. Thus, N-hydroxy-N-[(R)-2-[(2-pyridinylhydrazino)carbonyl]heptyl]formamide was prepared by reaction of (2R)-[(benzyloxyformylamino)methyl]heptanoic acid with 2-pyridinylhydrazine, followed by hydrogenation over Pd/C in MeOH.

IT 634608-75-6P 634609-50-0P 634609-51-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxy(hydrazinooxopropyl)formamide derivs. as peptide deformylase inhibitors with antibacterial activity)

RN 634608-75-6 HCAPLUS

CN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[4-methyl-6-(4-morpholinyl)-2-pyrimidinyl]hydrazide, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 634609-50-0 HCAPLUS
CN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[4-(dimethylamino)-6-methyl-2-pyrimidinyl]hydrazide, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 634609-51-1 HCAPLUS
CN Heptanoic acid, 2-[(formylhydroxyamino)methyl]-, 2-[4-(cyclopropylamino)-6-methyl-2-pyrimidinyl]hydrazide, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 118121-87-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydroxy(hydrazinooxopropyl)formamide derivs. as peptide deformylase inhibitors with antibacterial activity)
RN 118121-87-2 HCAPLUS
CN Morpholine, 4-(2-hydrazinyl-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:300520 HCAPLUS Full-text
DOCUMENT NUMBER: 134:311221
TITLE: Preparation of 2,4-diaminopyrimidines as gram-positive selective antibacterials.
INVENTOR(S): Ali, Amjad; Taylor, Gayle E.; Graham, Donald W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001028561	A1	20010426	WO 2000-US28786	20001018

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-160813P P 19991021
OTHER SOURCE(S): MARPAT 134:311221
GI



I

AB Title compds. [I; R1 = H, (substituted) alkyl, alkenyl, alkynyl, alicyclyl, heterocyclyl, aryl(alkyl), heteroaryl(alkyl), aryl(alkyl)amino, etc.; R3 = alicyclyl, heterocyclyl, (substituted) aryl(alkyl), heteroaryl(alkyl), aryl(alkyl)amino, heteroaryl(alkyl)amino; R4 = H, alkyl], were prepared Thus, 2-amino-4,6-dichloropyrimidine and 3-ethyl-4-methylaniline were refluxed in EtOH to give 2-amino-4-chloro-6-(3-ethyl-4-methylanilino)pyrimidine. The latter was refluxed with K2CO3 and 4-bromophenol in EtOH to give 2-amino-4-(4-bromophenoxy)-6-(3-ethyl-4-methylanilino)pyrimidine. I inhibited DNA polymerase III in the range of 2-25 μM.

IT 335444-75-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-diaminopyrimidines as gram-pos. selective antibacterials)
RN 335444-75-2 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-iodo-4-methylphenyl)-6-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:331924 HCAPLUS Full-text
DOCUMENT NUMBER: 125:86587
ORIGINAL REFERENCE NO.: 125:16329a,16332a
TITLE: Pyrrolo[2,3-d]pyrimidines and pyrido[2,3-d]pyrimidines as conformationally restricted analogs of the antibacterial agent trimethoprim
AUTHOR(S): Kuyper, Lee F.; Garvey, Janice M.; baccanari, David P.; Champness, John N.; Stammers, David K.; Beddell, Christopher R.
CORPORATE SOURCE: Research Triangle Park, Wellcome Research Laboratories, NC, 27709, USA
SOURCE: Bioorganic & Medicinal Chemistry (1996), 4(4), 593-602 CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Conformationally restricted analogs of the antibacterial agent trimethoprim (TMP) were designed to mimic the conformation of the drug observed in its

complex with bacterial dihydrofolate reductase (DHFR). This conformation of TMP was achieved by linking the 4-amino function to the methylene group by one- and two-carbon bridges. A pyrrolo[2,3-d]pyrimidine I, a dihydro analog, and a tetrahydropyrido[2,3-d]pyrimidine II were synthesized and tested as inhibitors of DHFR. One analog showed activity equivalent to that of TMP against DHFR from three species of bacteria. An X-ray crystal structure of this inhibitor bound to Escherichia coli DHFR was determined to evaluate the structural consequences of the conformational restriction.

IT 178551-68-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolo[2,3-d]pyrimidines and pyrido[2,3-d]pyrimidines as conformationally restricted analogs of the antibacterial agent trimethoprim)
RN 178551-68-3 HCAPLUS
CN Benzeneacetaldehyde, 3,4,5-trimethoxy-, N-2-(2-amino-6-methyl-4-pyrimidinyl)hydrazone (CA INDEX NAME)



IT 28840-64-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant in the preparation of pyrrolo[2,3-d]pyrimidines and pyrido[2,3-d]pyrimidines as conformationally restricted analogs of the antibacterial agent trimethoprim)
RN 28840-64-4 HCAPLUS
CN 2-Pyrimidinamine, 4-hydrazinyl-6-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (21 CITINGS)

L24 ANSWER 9 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:782515 HCAPLUS Full-text
DOCUMENT NUMBER: 124:29691
ORIGINAL REFERENCE NO.: 124:5699a,5702a
TITLE: Synthesis of certain 1,2,3-selenadiazole, 1,2,3-thiadiazole and 1,2-oxazoline derivatives of anticipated antibacterial activity
AUTHOR(S): Kandeel, Manal M.; El-Meligie, Salwa; Omar, Refaat H.; Roshdy, Sameha A.; Youssef, Khairia M.

CORPORATE SOURCE: Faculty of Pharmacy, Cairo University, Cairo, 11562, Egypt
SOURCE: Zagazig Journal of Pharmaceutical Sciences (1994), 3(3B), 197-205
CODEN: ZJPSEV; ISSN: 1110-5089
PUBLISHER: University of Zagazig, Faculty of Pharmacy
DOCUMENT TYPE: Journal
LANGUAGE: English
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB 1,2,3-Selena(or thia-)diazoles, e.g. I and II [R = 2-amino-6-methyl-4-pyrimidinyl (Q), 4-amino-2-quinazolinyl (Q1); X = Se, S], were prepared by reaction of chloro pyrimidines and quinazolines, e.g. 2,4-dichloro-6-methylpyrimidine, with II (R = H; X = Se, S) . As a second approach, semicarbazones, e.g. III, react with SeO2 to give selenadiazoles, e.g. II. Chalcone analogs IV and 1,2-oxazolines V (Ar = Q, Q1, Ar1 = Ph, 2-ClC6H4, 4-MeOC6H4, etc.) were prepared Antimicrobial screening of some of these compds. showed significant activity.

IT 171797-41-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bactericidal activity of selenadiazoles, thiadiazoles, and oxazolines)
RN 171797-41-4 HCAPLUS
CN Hydrazinecarboxamide, 2-[1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]ethylidene]- (CA INDEX NAME)



IT 171797-35-6P 171797-53-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of selenadiazoles, thiadiazoles, and oxazolines)
RN 171797-35-6 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[4-(1,2,3-selenadiazol-4-yl)phenyl]- (CA INDEX NAME)



RN 171797-53-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-(4,5-dihydro-5-phenyl-3-isoxazolyl)phenyl]-6-methyl- (CA INDEX NAME)



IT 131554-47-7P 131554-48-8P 144202-65-3P
144202-67-5P 144202-72-2P 171797-40-3P
171797-48-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and bactericidal activity of selenadiazoles, thiadiazoles, and oxazolines)

RN 131554-47-7 HCAPLUS
CN Ethanone, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 131554-48-8 HCAPLUS
CN Ethanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis- (9CI) (CA INDEX NAME)



RN 144202-65-3 HCAPLUS
CN 2-Propen-1-one, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-3-phenyl- (CA INDEX NAME)



RN 144202-67-5 HCAPLUS
CN 2-Propen-1-one, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-3-(2-chlorophenyl)- (CA INDEX NAME)



RN 144202-72-2 HCAPLUS
CN 2-Propen-1-one, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-3-[4-(dimethylamino)phenyl]- (CA INDEX NAME)



RN 171797-40-3 HCAPLUS
CN Hydrazinecarboxamide, 2,2'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenyleneethylidyne)]bis- (9CI) (CA INDEX NAME)



RN 171797-48-1 HCAPLUS
CN 2-Propen-1-one, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-3-(4-methoxyphenyl)- (CA INDEX NAME)



IT 171797-34-5P 171797-38-9P 171797-54-9P
171797-55-0P 171797-56-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and bactericidal activity of selenadiazoles, thiadiazoles, and oxazolines)
RN 171797-34-5 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N2,N4-bis[4-(1,2,3-selenadiazol-4-yl)phenyl]- (CA INDEX NAME)



RN 171797-38-9 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[4-(1,2,3-thiadiazol-4-yl)phenyl]- (CA INDEX NAME)



RN 171797-54-9 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[5-(2-chlorophenyl)-4,5-dihydro-3-isoxazolyl]phenyl]-6-methyl- (CA INDEX NAME)



RN 171797-55-0 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[4,5-dihydro-5-(4-methoxyphenyl)-3-

isoxazolyl]phenyl]-6-methyl- (CA INDEX NAME)



RN 171797-56-1 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[4-[5-[4-(dimethylamino)phenyl]-4,5-dihydro-3-isoxazolyl]phenyl]-6-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L24 ANSWER 10 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:612210 HCAPLUS Full-text
DOCUMENT NUMBER: 123:228093
ORIGINAL REFERENCE NO.: 123:40743a,40746a
TITLE: Synthesis and antitumor activity of some substituted pyrimidines
AUTHOR(S): Youssef, K. M.; Abou-Sier, A. H.; Essawi, M. Y. H.; Shouman, S.
CORPORATE SOURCE: Faculty Pharmacy, Cairo University, Cairo, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 383-91
CODEN: EJPSBZ; ISSN: 0301-5068
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis and in vitro antitumor and antibacterial activity of 2-amino-4-(amino or substituted amino)-6-(3,4,5- trimethoxybenzoylamino)pyrimidines and of 4-(amino or substituted amino)-6-methyl-2-(3,4,5-trimethoxybenzoylamino)pyrimidines is described. Two of the compds. showed

significant cytotoxic activity against Ehrlich ascites tumor cells, whereas others showed considerable antibacterial effect.

IT 168197-66-8P 168197-67-9P 168197-68-0P
168197-69-1P 168197-72-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and antitumor and antibacterial activity of some substituted pyrimidines)

RN 168197-66-8 HCAPLUS
CN Benzamide, N-(4-amino-6-methyl-2-pyrimidinyl)-3,4,5-trimethoxy- (CA INDEX NAME)



RN 168197-67-9 HCAPLUS
CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-6-(1-pyrrolidinyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 168197-68-0 HCAPLUS
CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 168197-69-1 HCAPLUS
CN Benzamide, 3,4,5-trimethoxy-N-[4-methyl-6-(1-piperidinyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 168197-72-6 HCAPLUS
CN Benzamide, N-[4-[[4-(4-chlorophenyl)-2,5-dioxo-1-piperazinyl]amino]-6-methyl-2-pyrimidinyl]-3,4,5-trimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L24 ANSWER 11 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1992:612434 HCAPLUS Full-text
DOCUMENT NUMBER: 117:212434
ORIGINAL REFERENCE NO.: 117:36699a,36702a
TITLE: Synthesis of some 4-substituted-pyrimidinylaminophenyl-6-aryl-1,2,5,6-tetrahydro-2-thioxopyrimidine derivatives as possible antimicrobial agents
AUTHOR(S): Youssef, K. M.; Badran, M. M.
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1992), 33(1-2), 121-8
CODEN: EJPSBZ; ISSN: 0301-5068
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III

AB A novel series of title compds. I [R = Ph, 2-, 4-ClC6H4, 2-MeOC6H4, 2,6-(MeO)2C6H3, 3-O2NC6H4) was synthesized. Treatment of 2-amino-4-chloro-6-methylpyrimidine with p-aminoacetophenone afforded the corresponding key intermediate II. The latter reacted with RCHO to yield the chalcone analogs III which underwent cyclocondensation with thiourea to furnish the target compds. I. Preliminary antimicrobial screening showed that some of these novel thioxopyrimidines and III possess moderate activity against certain gram pos. bacteria.

IT 144202-66-4P 144202-78-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activity of)

RN 144202-66-4 HCAPLUS
CN 2(1H)-Pyrimidinethione, 4-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-5,6-dihydro-6-phenyl- (CA INDEX NAME)



RN 144202-78-8 HCAPLUS
CN 2(1H)-Pyrimidinethione, 4-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-6-[4-(dimethylamino)phenyl]-5,6-dihydro- (CA INDEX NAME)



IT 144202-65-3P 144202-68-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, cyclocondensation with thiourea and bactericidal and fungicidal activity of)

RN 144202-65-3 HCAPLUS
CN 2-Propen-1-one, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-3-phenyl- (CA INDEX NAME)



RN 144202-68-6 HCAPLUS
CN 2-Propen-1-one, 1-[4-[(2-amino-6-methyl-4-pyrimidinyl)amino]phenyl]-3-(4-chlorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L24 ANSWER 12 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:143326 HCAPLUS Full-text
DOCUMENT NUMBER: 114:143326
ORIGINAL REFERENCE NO.: 114:24321a,24324a
TITLE: Synthesis of certain N-aryl-N'-(2-pyrimidinyl)guanidine derivatives as potential antimicrobial agents
AUTHOR(S): Eisa, H. M.; Tayel, M. A.; Yousif, M. Y.; El-Kerdawy, M. M.
CORPORATE SOURCE: Fac. PHarm., Univ. Mansoura, Mansoura, Egypt
SOURCE: Zhonghua Yaoxue Zazhi (1990), 42(5), 385-9
CODEN: CYHCEX; ISSN: 1016-1015
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Title compds. I (R = 4-EtO, 2-Br, 3-NO2; R1 = OH, arylamino, R2 = arylhydrazono, H; R1 = Cl, R2 = H) were prepared from RC6H4NHC(:NH)NHC(:NH)NH2 by various methods. Antimicrobial testing of some of I against pathogenic microorganisms revealed only two compds. that have a marked effect against Escherichia coli.
IT 131699-85-9P 131699-88-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)
RN 131699-85-9 HCAPLUS
CN Guanidine, N-(2-bromophenyl)-N'-[4-[(4-chlorophenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 131699-88-2 HCAPLUS
CN Guanidine, N-[4-methyl-6-[(4-nitrophenyl)amino]-2-pyrimidinyl]-N'-(3-nitrophenyl)- (CA INDEX NAME)



L24 ANSWER 13 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:62045 HCAPLUS Full-text
DOCUMENT NUMBER: 114:62045
ORIGINAL REFERENCE NO.: 114:10647a
TITLE: Synthesis of certain N-aryl-N'-(2-pyrimidinyl)guanidine derivatives as potential antimicrobial agents
AUTHOR(S): Eisa, H. M.; Tayel, M. A.; Yousif, M. Y.; El-Kerdawy, M. M.
CORPORATE SOURCE: Fac. Pharm., Univ. Mansoura, Mansoura, Egypt
SOURCE: Archives of Pharmacal Research (1990), 13(1), 78-81
CODEN: APHRDQ; ISSN: 0253-6269
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:62045
GI



AB The title compds. I (R = 4-EtO, 2-Br, 3-NO2; R1 = OH, R2 = H) were prepared by cyclization of N-arylbiguanides II with EtO2CCH2COMe. Coupling of I (R2 = H) with R3N:N+ Cl- (R3 = 2-MeOC6H4, 2,4-Cl2C6H3) gave guanidines I (R1 = OH, R2 = NNHR3). Chlorination of I (R1 = OH) with POCl3 gave I (R1 = Cl) which further reacted with R4NH2 (R4 = 4-ClC6H4, 4-NO2C6H4) to give I (R1 = NHR4). Antimicrobial testing of these compds. against pathogenic microorganisms revealed that only two have a marked effect against E. coli.
IT 131699-85-9P 131699-88-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial activity of)

RN 131699-85-9 HCAPLUS
CN Guanidine, N-(2-bromophenyl)-N'-[4-[(4-chlorophenyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 131699-88-2 HCAPLUS
CN Guanidine, N-[4-methyl-6-[(4-nitrophenyl)amino]-2-pyrimidinyl]-N'-(3-nitrophenyl)- (CA INDEX NAME)



L24 ANSWER 14 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1991:62037 HCAPLUS Full-text
DOCUMENT NUMBER: 114:62037
ORIGINAL REFERENCE NO.: 114:10643a,10646a
TITLE: Synthesis of some Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines as potential biodynamic agents
AUTHOR(S): Ghoneim, Khadiga M.; El-Telbany, Farag A.; Youssef, Khairia
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Chemistry (1989), Volume Date 1987, 30(6), 295-304
CODEN: EGJCA3; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis of certain Mannich bases of 2- and 4-amino- and 2,4-diamino-6-methylpyrimidines and their antimicrobial and antileukemic activities are described. Likewise, application of the Mannich conditions to 2-amino-4-(p-hydroxyanilino)-, 4-amino-2-(p-hydroxyanilino)-, and 2-amino-4-(p-acetylanilino)-6-methylprimidines using piperazine as the secondary amine afforded the corresponding bis-Mannich bases.

IT 81080-17-3P 81080-39-9P 131554-45-5P
131554-48-8P 131555-88-9P 131555-93-6P
131555-94-7P 131555-95-8P 131555-96-9P
131555-97-0P 131556-04-2P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and antibacterial and antifungal activity of)

RN 81080-17-3 HCAPLUS

CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-2-(1-pyrrolidinylmethyl)- (CA INDEX NAME)



RN 81080-39-9 HCAPLUS

CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-2-[(diethylamino)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 131554-45-5 HCAPLUS

CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-2-(4-morpholinylmethyl)- (CA INDEX NAME)



RN 131554-48-8 HCAPLUS

CN Ethanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis- (9CI) (CA INDEX NAME)



RN 131555-88-9 HCAPLUS

CN Ethanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis-, monohydrochloride (9CI) (CA INDEX NAME)



RN 131555-93-6 HCAPLUS
CN 1-Propanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis[3-(diethylamino)- (9CI) (CA INDEX NAME)



RN 131555-94-7 HCAPLUS
CN 1-Propanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis[3-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 131555-95-8 HCAPLUS
CN 1-Propanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis[3-(4-morpholinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 131555-96-9 HCAPLUS
CN 1-Propanone, 1,1'-[(6-methyl-2,4-pyrimidinediyl)bis(imino-4,1-phenylene)]bis[3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 131555-97-0 HCAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)



RN 131556-04-2 HCAPLUS
CN Phenol, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]-2-(4-morpholinylmethyl)-, hydrochloride (1:1) (CA INDEX NAME)



IT 1791-73-7DP, 2,4-Diamino-6-methylpyrimidine, Mannich bases
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antimicrobial and antileukemic activity of)
RN 1791-73-7 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 15 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1988:204585 HCAPLUS Full-text
DOCUMENT NUMBER: 108:204585
ORIGINAL REFERENCE NO.: 108:33621a,33624a
TITLE: Synthesis and evaluation of some 2-, 4-, and 2,4-disubstituted-6-methylpyrimidine derivatives for antimicrobial activity
AUTHOR(S): Ghoneim, Khadiga M.; El-Telbany, Farag; Youssef, Khairia
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Pharmaceutical Sciences (1987), 28(1-4), 117-26
CODEN: EJPSBZ; ISSN: 0301-5068
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:204585
GI



AB Chloropyrimidines were treated with amines to give pyrimidinediamines I (R1 = NHCONH2, xylyl, EtOC6H4, pyridyl, dimethylisoxazolyl), II (R2 = xylyl, MeCOC6H4), and III (R3 = xylyl, EtOC6H4, dimethylisoxazolyl). Some I and II showed bactericidal and fungicidal activity.

IT 89489-17-8P 112521-41-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 89489-17-8 HCAPLUS

CN Hydrazinecarboxamide, 2-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 112521-41-2 HCAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



IT 112521-50-3P 112521-55-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activity of)

RN 112521-50-3 HCAPLUS

CN Ethanone, 1-[4-[(4-amino-6-methyl-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 112521-55-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-ethoxyphenyl)-6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



L24 ANSWER 16 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1988:56043 HCAPLUS Full-text
DOCUMENT NUMBER: 108:56043
ORIGINAL REFERENCE NO.: 108:9365a
TITLE: Synthesis and evaluation of some 2-, 4- and 2,4-di-substituted-6-methylpyrimidine derivatives for antimicrobial activity
AUTHOR(S): Ghoneim, Khadiga M.; El-Telbany, Farag; Youssef, Khairia
CORPORATE SOURCE: Fac. Pharm., Cairo Univ., Cairo, Egypt
SOURCE: Journal of the Indian Chemical Society (1986), 63(10), 914-17
CODEN: JICSAH; ISSN: 0019-4522
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:56043
GI



AB Pyrimidinediamines I (R1 = aryl, R2 = H; and R1 = H, R2 = ureido, aryl, pyridyl) were prepared from chloropyrimidines. I showed their usefulness as bactericides.
IT 6301-29-7P 6303-40-8P 89489-17-8P
96716-32-4P 112521-39-8P 112521-40-1P
112521-41-2P 112521-42-3P 112521-43-4P
112521-48-9P 112521-49-0P 112521-50-3P

112521-51-4P 112521-52-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)

RN 6301-29-7 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(2,5-dimethylphenyl)-6-methyl- (CA INDEX NAME)



RN 6303-40-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(3-ethoxyphenyl)-6-methyl- (CA INDEX NAME)



RN 89489-17-8 HCAPLUS
CN Hydrazinecarboxamide, 2-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 96716-32-4 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(3,4-dimethylphenyl)-6-methyl- (CA INDEX NAME)



RN 112521-39-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(2,4-dimethylphenyl)-6-methyl- (CA INDEX NAME)



RN 112521-40-1 HCAPLUS
CN Hydrazinecarbothioamide, 2-(2-amino-6-methyl-4-pyrimidinyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 112521-41-2 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 112521-42-3 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-4-pyridinyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 112521-43-4 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-(3,5-dimethyl-4-isoxazolyl)-6-methyl- (CA INDEX NAME)



RN 112521-48-9 HCAPLUS
CN Thiourea, N-(4-methylphenyl)-N'-[4-methyl-6-(phenylamino)-2-pyrimidinyl]- (CA INDEX NAME)



RN 112521-49-0 HCAPLUS
CN Thiourea, N-[4-methyl-6-(phenylamino)-2-pyrimidinyl]-N'-phenyl- (CA INDEX NAME)



RN 112521-50-3 HCAPLUS
CN Ethanone, 1-[4-[(4-amino-6-methyl-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 112521-51-4 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(2,4-dimethylphenyl)-6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 112521-52-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(3,4-dimethylphenyl)-6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L24 ANSWER 17 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1981:497712 HCAPLUS Full-text
DOCUMENT NUMBER: 95:97712
ORIGINAL REFERENCE NO.: 95:16419a,16422a
TITLE: 2,4-Bis(arylamino)-6-methylpyrimidines as antimicrobial agents
AUTHOR(S): Ghosh, Dolly
CORPORATE SOURCE: Dep. Chem., Bose Inst., Calcutta, 700 009, India
SOURCE: Journal of the Indian Chemical Society (1981), 58(5), 512-13
CODEN: JICSAH; ISSN: 0019-4522
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Pyrimidines I (R = aryl, R1 = Me, H; R2 = H, Me) were synthesized. All were tested against some gram-pos. and gram-neg. bacteria and Candida albicans. 2,4-Bis(p-chloroanilino)- and 2,4-bis(p-bromoanilino)pyrimidine derivs. possess significant activity.

IT 78830-62-3P 78830-63-4P 78830-64-5P
78830-65-6P 78830-66-7P 78830-68-9P
78830-69-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activities of)

RN 78830-62-3 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N2,N4-diphenyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 78830-63-4 HCAPLUS
CN Phenol, 4,4'-[(6-methyl-2,4-pyrimidinediyl)diimino]bis-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 78830-64-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N2,N4-bis(4-methoxyphenyl)-6-methyl- (CA INDEX NAME)



RN 78830-65-6 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N2,N4-bis(4-methylphenyl)- (CA INDEX NAME)



RN 78830-66-7 HCAPLUS
CN Benzenesulfonamide, 4,4'-[(6-methyl-2,4-pyrimidinediyl)diimino]bis- (9CI) (CA INDEX NAME)



RN 78830-68-9 HCAPLUS
CN 2,4-Pyrimidinediamine, N2,N4-bis(4-bromophenyl)-6-methyl- (CA INDEX NAME)



RN 78830-69-0 HCAPLUS
CN 2,4-Pyrimidinediamine, N2,N4-bis(2-chlorophenyl)-6-methyl-, hydrochloride (1:1) (CA INDEX NAME)



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

L24 ANSWER 18 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1980:34952 HCAPLUS Full-text
DOCUMENT NUMBER: 92:34952
ORIGINAL REFERENCE NO.: 92:5771a,5774a
TITLE: Correlation analysis of pyrimidine folic acid antagonists as antibacterial agents. II. Classification by mode of action using discriminant analysis
AUTHOR(S): Smith, Carl C.; Genther, Clara S.; Coats, Eugene A.

CORPORATE SOURCE: Dep. Environ. Health, Univ. Cincinnati, Cincinnati, OH, 45267, USA
SOURCE: European Journal of Medicinal Chemistry (1979), 14(3), 271-6
CODEN: EJMCA5; ISSN: 0009-4374
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The ability of folic acid [59-30-3] or folinic acid [58-05-9] to reverse the inhibitory effect of pyrimidines against Streptococcus faecium, Lactobacillus casei, and Pediococcus cerevisiae was studied. an amino group at the 2-position of the pyrimidine nucleus was related to reversible antifolate action in all 3 organisms Ph or anilino substituents at the 6-position resulted in irreversible antibacterial activity against L. casei and P cerevisiae, but was not significant against S. faecium. Discriminant anal. as an adjunct to regression anal. in characterization of structure-activity relations of pyrimidines in quant. terms is discussed.

IT 42388-78-3 42388-88-5 51386-96-0
51387-20-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, folate reversal of, structure in relation to)

RN 42388-78-3 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(butylmethylamino)ethyl]-N2-(5,6-dichloro-1H-benzimidazol-2-yl)-6-methyl- (CA INDEX NAME)



RN 42388-88-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(5,6-dichloro-1H-benzimidazol-2-yl)-N4-[4-(diethylamino)-1-methylbutyl]-6-methyl- (CA INDEX NAME)



RN 51386-96-0 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-(dimethylamino)propyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51387-20-3 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[1-(1-ethyl-4-piperidinyl)ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



L24 ANSWER 19 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1980:34951 HCAPLUS Full-text
DOCUMENT NUMBER: 92:34951
ORIGINAL REFERENCE NO.: 92:5771a,5774a
TITLE: Correlation analysis of pyrimidine folic acid antagonists as antibacterial agents. I
AUTHOR(S): Coats, Eugene A.; Genther, Clara S.; Smith, Carl C.
CORPORATE SOURCE: Coll. Pharm., Univ. Cincinnati, Cincinnati, OH, 45267, USA
SOURCE: European Journal of Medicinal Chemistry (1979), 14(3), 261-70
CODEN: EJMCA5; ISSN: 0009-4374
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The activities of 175 pyrimidines as inhibitors of Streptococcus faecium, Lactobacillus casei, and Pediococcus cerevisiae are reported. In addition, the mode of action according to the ability of folic acid [59-30-3] or folinic acid [58-05-9] to reverse the inhibitory effect of the pyrimidines was determined The 2,4-diamino substituent pattern appeared to be the dominant but not the sole factor controlling mode of action. Quant. structure-activity relations using regression anal., substituent consts., and indicator variables were developed in an effort to delineate influences on potency and to quant. differences between the test systems. Although aromatic and(or) lipophilic substituents at the 5 position of 2,4-diaminopyrimidines enhanced folate reversible inhibition against all 3 systems the derived equations quant. establish differences in and limitations on the extent of this effect.

IT 4364-73-2 21062-28-2 42388-72-7
42388-78-3 42388-88-5 42389-03-7
42389-09-3 42389-13-9 42389-19-5
42389-23-1 51386-70-0 51386-71-1
51386-72-2 51386-76-6 51386-77-7
51386-78-8 51386-80-2 51386-82-4
51386-90-4 51386-94-8 51386-95-9
51386-96-0 51387-18-9 51387-20-3

51387-40-7 51387-67-8 51387-78-1
51475-54-8 71523-77-8 71523-79-0
71523-80-3 71523-81-4 71523-82-5
71523-83-6 71523-84-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, structure in relation to)

RN 4364-73-2 HCAPLUS
CN Guanidine, N-(4-chlorophenyl)-N'-[4-[[2-(diethylamino)ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 21062-28-2 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[(1-ethyl-3-piperidinyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 42388-72-7 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(6-chloro-1H-benzimidazol-2-yl)-6-methyl-N4-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 42388-78-3 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(butylmethylamino)ethyl]-N2-(5,6-dichloro-1H-benzimidazol-2-yl)-6-methyl- (CA INDEX NAME)



RN 42388-88-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(5,6-dichloro-1H-benzimidazol-2-yl)-N4-[4-(diethylamino)-1-methylbutyl]-6-methyl- (CA INDEX NAME)



RN 42389-03-7 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(5,6-dichloro-1H-benzimidazol-2-yl)-6-methyl-N4-(1-methyl-3-piperidinyl)- (CA INDEX NAME)



RN 42389-09-3 HCAPLUS
CN 1H-Benzimidazol-2-amine, N-(4-[1,4'-bipiperidin]-1'-yl-6-methyl-2-pyrimidinyl)-5,6-dichloro- (CA INDEX NAME)



RN 42389-13-9 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(diethylamino)ethyl]-6-methyl-N2-(4,5,6,7-tetrachloro-1H-benzimidazol-2-yl)- (CA INDEX NAME)



RN 42389-19-5 HCAPLUS
CN 2,4-Pyrimidinediamine, N4-[2-(diethylamino)ethyl]-6-methyl-N2-[6-(trifluoromethyl)-1H-benzimidazol-2-yl]- (CA INDEX NAME)



RN 42389-23-1 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(5,6-dimethyl-1H-benzimidazol-2-yl)-N4-(1-ethyl-3-piperidinyl)-6-methyl- (CA INDEX NAME)



RN 51386-70-0 HCAPLUS
CN Guanidine, N-(4-chlorophenyl)-N'-[4-[(1-ethyl-3-piperidinyl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-71-1 HCAPLUS
CN Guanidine, N-(4-chlorophenyl)-N'-[4-[[4-(dimethylamino)cyclohexyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-72-2 HCAPLUS
CN Guanidine, N-[4-[[2-[bis(1-methylethyl)amino]ethyl]amino]-6-methyl-2-pyrimidinyl]-N'-(4-chlorophenyl)- (CA INDEX NAME)



RN 51386-76-6 HCAPLUS
CN Guanidine, N-(4-chlorophenyl)-N'-[4-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-77-7 HCAPLUS
CN Guanidine, N-(4-chlorophenyl)-N'-[4-[[3-[(diethylamino)methyl]-4-methoxyphenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-78-8 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-(diethylamino)ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-80-2 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-(di-2-propen-1-ylamino)ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-82-4 HCAPLUS
CN Guanidine, N-[4-[[2-[bis(1-methylethyl)amino]ethyl]amino]-6-methyl-2-pyrimidinyl]-N'-(3,4-dichlorophenyl)- (CA INDEX NAME)



RN 51386-90-4 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-[(2-hydroxy-2-methylpropyl)amino]ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-94-8 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-[ethyl(2-hydroxy-2-methylpropyl)amino]ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-95-9 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-(dimethylamino)-1-methylethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51386-96-0 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-(dimethylamino)propyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51387-18-9 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-methyl-6-[[(1-methyl-2-piperidinyl)methyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)



RN 51387-20-3 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[1-(1-ethyl-4-piperidinyl)ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51387-40-7 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[3-[(diethylamino)methyl]phenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51387-67-8 HCAPLUS
CN Guanidine, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[4-[[2-(hexahydro-1H-azepin-1-yl)ethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51387-78-1 HCAPLUS
CN Guanidine, N-(4-chloro-1-naphthalenyl)-N'-[4-[[3-[(diethylamino)methyl]-4-methoxyphenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 51475-54-8 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[4-[(diethylamino)methyl]phenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 71523-77-8 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(4-chloro-1-naphthalenyl)-N4-[3-[(diethylamino)methyl]-4-methoxyphenyl]-6-methyl- (CA INDEX NAME)



RN 71523-79-0 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(3,4-dichlorophenyl)-N4-[3-[(diethylamino)methyl]-4-methoxyphenyl]-6-methyl- (CA INDEX NAME)



RN 71523-80-3 HCAPLUS
CN 2,4-Pyrimidinediamine, N2-(3,4-dichlorophenyl)-N4-[3-(diethylamino)propyl]-6-methyl- (CA INDEX NAME)



RN 71523-81-4 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[2-(dipropylamino)-1-methylethyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 71523-82-5 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[[4-[(diethylamino)methyl]-3-ethoxyphenyl]amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



RN 71523-83-6 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-methyl-6-[[4-(1-pyrrolidinyl)-2-piperidinyl]amino]-2-pyrimidinyl]- (CA INDEX NAME)



RN 71523-84-7 HCAPLUS
CN Guanidine, N-(3,4-dichlorophenyl)-N'-[4-[(hexahydro-4-methyl-1H-azepin-1-yl)amino]-6-methyl-2-pyrimidinyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L24 ANSWER 20 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1964:486219 HCAPLUS Full-text
DOCUMENT NUMBER: 61:86219
ORIGINAL REFERENCE NO.: 61:15066h,15067a-c
TITLE: Effect of a number of N-pyrimidyl amino acids and of some of their 5-arylazo derivatives on the growth of certain microorganisms
AUTHOR(S): Roy-Burman, P.; Sen, D.
CORPORATE SOURCE: Univ. Coll. Sci. Technol., Calcutta
SOURCE: Biochemical Pharmacology (1964), 13(10), 1437-49
CODEN: BCPCA6; ISSN: 0006-2952
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Sixteen new N-pyrimidyl amino acids were obtained by substitution at the C-2, C-4, or C-6 position of 2,4-diamino-6-methylpyrimidine by aromatic amino acids or different carboxyalkyl amino groups (i.e., aliphatic amino acid moiety). These compds. were tested for their effect on the growth of Streptococcus faecalis, Lactobacillus arabinosus, and Escherichia coli. The new compds., 2,4-diamino-5-arylazo-6-methylpyrimidine and six N-(5-arylazo-4-pyrimidyl) amino acids, were also studied. 2,4-Diamino-6-methylpyrimidine inhibited growth of all 3 microorganisms tested, but substitution at the C-2, C-4, or C-6 position by carboxyalkyl amino groups produced compds. with little or no inhibitory effects. The three N-pyrimidyl compds. substituted with aromatic amino acids inhibited growth but were less effective than the parent compound All the 5-arylazopyrimidines significantly inhibited growth of S. faecalis and, to a lesser extent, L. arabinosus. It was observed that among these

compds. the inhibitory activity decreased with increase in the bulk of the amino acid moiety. Investigation of the mechanism of the inhibitory action of these compds. in S. faecalis revealed that they acted primarily as folic acid antagonists in a manner consistent with an assumption that they interfere with the enzymic conversion of folic acid to N5-formyltetrahydrofolic acid in S. faecalis.

IT 89897-36-9P, Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)-
90000-53-6P, Glycine, N-(4-amino-6-methyl-2-pyrimidinyl)-,
hydrazide 90198-25-7P, Alanine,
N-(2-amino-6-methyl-4-pyrimidinyl)- 90198-26-8P, Alanine,
N-(4-amino-6-methyl-2-pyrimidinyl)- 90198-46-2P, Serine,
N-(2-amino-6-methyl-4-pyrimidinyl)- 90198-47-3P, Serine,
N-(4-amino-6-methyl-2-pyrimidinyl)- 90649-20-0P, Butyric acid,
2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- 91141-61-6P,
Sulfanilic acid, N-(2-amino-6-methyl-4-pyrimidinyl)- 91253-20-2P
, Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- 91253-21-3P,
Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- 91560-28-0P,
Benzoic acid, p-[(2-amino-6-methyl-4-pyrimidinyl)amino]-
91560-29-1P, Benzoic acid,
p-[(4-amino-6-methyl-2-pyrimidinyl)amino]- 91717-29-2P,
Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- 92296-32-7P,
Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl-
92296-33-8P, Alanine, N-(4-amino-6-methyl-2-pyrimidinyl)-3-phenyl-
, DL-
RL: PREP (Preparation)
(preparation and bactericidal activity of)

RN 89897-36-9 HCAPLUS
CN Glycine, N-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 90000-53-6 HCAPLUS
CN Glycine, N-(4-amino-6-methyl-2-pyrimidinyl)-, hydrazide (CA INDEX NAME)



RN 90198-25-7 HCAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 90198-26-8 HCAPLUS
CN Alanine, N-(4-amino-6-methyl-2-pyrimidinyl)- (CA INDEX NAME)



RN 90198-46-2 HCAPLUS
CN Serine, N-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 90198-47-3 HCAPLUS
CN Serine, N-(4-amino-6-methyl-2-pyrimidinyl)- (CA INDEX NAME)



RN 90649-20-0 HCAPLUS
CN Butanoic acid, 2-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 91141-61-6 HCAPLUS
CN Benzenesulfonic acid, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 91253-20-2 HCAPLUS
CN Isoleucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 91253-21-3 HCAPLUS
CN Leucine, N-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 91560-28-0 HCAPLUS
CN Benzoic acid, 4-[(2-amino-6-methyl-4-pyrimidinyl)amino]- (CA INDEX NAME)



RN 91560-29-1 HCAPLUS
CN Benzoic acid, 4-[(4-amino-6-methyl-2-pyrimidinyl)amino]- (CA INDEX NAME)



RN 91717-29-2 HCAPLUS
CN Valine, N-(2-amino-6-methyl-4-pyrimidinyl)- (CA INDEX NAME)



RN 92296-32-7 HCAPLUS
CN Alanine, N-(2-amino-6-methyl-4-pyrimidinyl)-3-phenyl- (6CI, 7CI) (CA INDEX NAME)



RN 92296-33-8 HCAPLUS
CN Alanine, N-(4-amino-6-methyl-2-pyrimidinyl)-3-phenyl- (7CI) (CA INDEX NAME)



L24 ANSWER 21 OF 21 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1957:86480 HCAPLUS Full-text
DOCUMENT NUMBER: 51:86480
ORIGINAL REFERENCE NO.: 51:15699h-i,15700a
TITLE: Synthetic compounds active against Salmonella-dysentery group bacilli
AUTHOR(S): Akiya, Shichiro
CORPORATE SOURCE: Univ. Tokyo
SOURCE: Japanese Journal of Experimental Medicine (1956), 26, 91-112
CODEN: JJEMAG; ISSN: 0021-5031

DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Synthetic organic compds. (1028) were tested for their in vitro antibacterial activities against Micrococcus pyogenes var. aureus, Escherichia coli Number 1, Shigella dysenteriae Ewing I, Shigella paradysenteriae 2a, Salmonella typhosa S 57, S. paratyphi A 1015, and S. enteritidis 5168. Of these compds. 436 were effective at 10-4M against at least one of the organisms. Active compds. comprised hydrazone derivative of 5-nitrofurfural, benzoquinone and naphthoquinone derivs., alkyl and acyl resorcinols, N-containing heteroarom. quaternary bases, aminodibenzofurans, hydrazones of pyridine derivs., aromatic aldazines, tricarbonylmethane derivs., and others.
IT 108840-85-3, Pyrimidine, 4-amino-6-methyl-2-(2-naphthylamino)-
108841-92-5, Pyrimidine, 2-amino-4-methyl-6-(2-naphthylamino)-
(bactericidal action of)
RN 108840-85-3 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N2-2-naphthalenyl- (CA INDEX NAME)



RN 108841-92-5 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-N4-2-naphthalenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

=> => d stat que l28
L1 STR



VAR G1=CH/10
NODE ATTRIBUTES:
NSPEC IS RC AT 8
NSPEC IS RC AT 9

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L3 9002 SEA FILE=REGISTRY SSS FUL L1
L6 STR



NODE ATTRIBUTES:
NSPEC IS C AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L7 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L8 STR



REP G1=(0-19) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L9 STR



REP G1=(0-19) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L10 STR



VAR G1=11/16/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L11 STR



VAR G1=11/16/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L13 4967 SEA FILE=REGISTRY SUB=L3 SSS FUL L6 OR L7 OR L8 OR L9 OR L10 OR L11
L14 STR



Page 1-A

Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L15 4 SEA FILE=REGISTRY SUB=L3 SSS FUL L14
L16 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L17 1 SEA FILE=REGISTRY SUB=L3 SSS FUL L16
L18 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L15
L19 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L17
L20 322253 SEA FILE=HCAPLUS ABB=ON PLU=ON "ANTIMICROBIAL AGENTS"/CV OR ANTIMICROB? OR DISINFECT? OR ANTISEPT? OR ANTIBACT? OR BACTERICID? OR BACTERIOSTAT? OR ("ANTIBACTERIAL AGENTS"/CV OR "ANTIBACTERIAL AGENTS (L) SYNERGISTIC"/CV OR "ANTIBACTERIOPHAGIC ACTION"/CV OR ANTISEPTICS/CV OR "BACTERICIDAL ACTION"/CV OR "BACTERICIDAL ACTION (L) SYNERGISTIC"/CV OR "BACTERICIDAL ACTION AND BACTERIOSTATIC ACTION"/CV OR "BACTERICIDAL ACTION

```
                OR BACTERIOSTATIC ACTION"/CV OR BACTERICIDES/CV OR "BACTERICIDE
                S, DISINFECTANTS AND ANTISEPTICS"/CV OR "BACTERICIDES,
                DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "BACTERICI
                DES, DISINFECTANTS, AND ANTISEPTICS"/CV OR "BACTERICIDES,
                DISINFECTANTS, AND ANTISEPTICS (L) SYNERGISTIC"/CV OR BACTERIOS
                TASIS/CV OR "DISINFECTANTS AND ANTISEPTICS"/CV OR "DISINFECTANT
                S AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "MICROBICIDAL AND
                MICROBIOSTATIC ACTION (L) BACTERIOSTATIC"/CV OR SPIROCHETICIDES
                /CV) OR GERMICID?
L21             3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L18 OR L19) AND L20
L22           738 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13
L23            23 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L22(L)L20
L24            21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23 NOT L21
L25          4031 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT (L13 OR L15 OR L17)
L26           411 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L25
L27            13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L26(L)L20
L28             5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L27 NOT (L21 OR L24)


=> d ibib abs hitstr l28 1-5

L28  ANSWER 1 OF 5  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         1993:38944  HCAPLUS  Full-text
DOCUMENT NUMBER:          118:38944
ORIGINAL REFERENCE NO.:   118:7103a,7106a
TITLE:                    Preparation of aralkylaminopyrimidines as bactericides
INVENTOR(S):              Fujii, Katsutoshi; Fukuda, Yasuhisa; Yamanaka,
                          Yoshinori
PATENT ASSIGNEE(S):       Ube Industries, Ltd., Japan
SOURCE:                   Jpn. Kokai Tokkyo Koho, 10 pp.
                          CODEN: JKXXAF
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     JP 04235976           A     19920825    JP 1991-73547          19910118
     JP 2762430            B2    19980604
PRIORITY APPLN. INFO.:                       JP 1991-73547          19910118
OTHER SOURCE(S):          CASREACT 118:38944; MARPAT 118:38944
GI
```



I

II



III

AB The title compds. I (R1 = H, halo, alkyl; R2 = halo, alkyl; R1R2 = (S-containing) (un)saturated 5- or 6-membered ring; R3 = H, (cyclo)alkyl, alkylthio, (alkyl-substituted) amino; R4 = (halo)alkyl, cycloalkyl; R5 = H, halo; R6 = H, halo, alkyl, (halo)alkoxy; n = 1, 2), useful as bactericides (no data), are prepared by treating pyrimidines II (X = eliminating group) with aralkylamines III in alc. solvents. Refluxing a mixture of II (R1 = X = Cl, R2 = Me, R3 = H), dl-α-ethyl-4-difluoromethoxybenzylamine, and Et3N in EtOH for 7 h gave 90% 5-chloro-6-methyl-4-(α-ethyl-4-difluoromethoxybenzylamino)pyrimidine.

IT 130339-42-3P 144992-10-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as bactericide)

RN 130339-42-3 HCAPLUS
CN 2,4-Pyrimidinediamine, 5-butyl-N4-[[4-(difluoromethoxy)phenyl]methyl]-N2,N2,6-trimethyl- (CA INDEX NAME)



RN 144992-10-9 HCAPLUS
CN 2,4-Pyrimidinediamine, 5-butyl-N4-[[4-(difluoromethoxy)phenyl]methyl]-6-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

L28 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1984:2643 HCAPLUS Full-text
DOCUMENT NUMBER: 100:2643
ORIGINAL REFERENCE NO.: 100:459a,462a
TITLE: X-ray studies of the binding of trimethoprim, methotrexate, pyrimethamine and two trimethoprim analogs to bacterial dihydrofolate reductase
AUTHOR(S): Baker, D. J.; Beddell, C. R.; Champness, J. N.; Goodford, P. J.; Norrington, F. E.; Roth, B.; Stammers, D. K.
CORPORATE SOURCE: Wellcome Res. Lab., Beckenham/Kent, UK
SOURCE: Chem. Biol. Pteridines, Proc. Int. Symp. Pteridines Folic Acid Deriv.: Chem., Biol. Clin. Aspects, 7th (1983), Meeting Date 1982, 545-9. Editor(s): Blair, John A. de Gruyter: Berlin, Fed. Rep. Ger.
CODEN: 50NHAH

DOCUMENT TYPE: Conference
LANGUAGE: English
AB Crystals were obtained of Escherichia coli dihydrofolate reductase complexed with the 3 drugs methotrexate, trimethoprim, pyrimethamine and also with 2 analogs of trimethoprim. Electron d. maps of the structures were obtained by isomorphous replacement and difference Fourier techniques. Kendrew skeletal models of the enzyme and the 5 inhibitors were fitted to their electron d. maps. The small modifications in the diaminopyrimidine rings of the 2 trimethoprim analogs are examined in the light of the decrease, relative to trimethoprim, of inhibitor potency against dihydrofolate reductase.
IT 21822-27-5
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(dihydrofolate reductase of Escherichia coli binding of, antibacterial activity in relation to)
RN 21822-27-5 HCAPLUS
CN 2,4-Pyrimidinediamine, 6-methyl-5-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L28 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1980:163926 HCAPLUS Full-text
DOCUMENT NUMBER: 92:163926
ORIGINAL REFERENCE NO.: 92:26573a,26576a
TITLE: 2,4-Diamino-5-benzylpyrimidines and analogs as antibacterial agents. 2. C-Alkylation of pyrimidines with Mannich bases and application to the synthesis of trimethoprim and analogs
AUTHOR(S): Roth, Barbara; Strelitz, Justina Z.; Rauckman, Barbara S.
CORPORATE SOURCE: Wellcome Res. Lab., Burroughs Wellcome Co., Research Triangle Park, NC, 27709, USA
SOURCE: Journal of Medicinal Chemistry (1980), 23(4), 379-84
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 92:163926
GI



I

AB A new route to 5-(p-hydroxybenzyl)pyrimidines was developed which utilizes phenolic Mannich bases plus pyrimidines containing at least two activating groups. The products were alkylated on the phenolic O or on the pyrimidine N-1 atom, depending on conditions. This method has been used to prepare trimethoprim (I), a broad-spectrum antibacterial agent, starting from 2,4-diaminopyrimidine and 2,6-dimethoxyphenol. Dihydrofolate reductase inhibition and antibacterial activity were determined for some 5-(3,5-dimethoxy 4-substituted benzyl)pyrimidines.

IT 21822-27-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, dihydrofolate reductase inhibition, and antibacterial activity of)

RN 21822-27-5 HCAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-5-[(3,4,5-trimethoxyphenyl)methyl]- (CA INDEX NAME)



IT 33929-39-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, ethylation, dihydrofolate reductase inhibition, and antibacterial activity of)

RN 33929-39-4 HCAPLUS

CN Phenol, 4-[(2,4-diamino-6-methyl-5-pyrimidinyl)methyl]-2,6-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L28 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1980:128952 HCAPLUS Full-text
DOCUMENT NUMBER: 92:128952
ORIGINAL REFERENCE NO.: 92:21039a,21042a
TITLE: Pyrazolylpyrimidine derivatives
INVENTOR(S): Nishimura, Tamio; Miyamoto, Yoshiko; Oyama, Hiroshi; Yamamura, Hiroshi; Morita, Takeshi; Matsumoto, Kuniomi
PATENT ASSIGNEE(S): Hokko Chemical Industry Co., Ltd., Japan; Meiji Seika Kaisha, Ltd.

SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54115384	A	19790907	JP 1978-23413	19780228
JP 57051835	B	19821104		

PRIORITY APPLN. INFO.: JP 1978-23413 A 19780228
GI



I

AB Two hundred and nine title derivs. I [R = H, alkyl, Ph; R1 = H, alkyl, aralkyl; R2 = halo, 1-imidazolyl, ZR3 (Z = O, S, NH; R3 = H, alkyl, etc.)] were prepared Antibacterial data of I were given against Piricularia oryzae, Helminthosporium oryzae, and Sphaerotheca fuliginea. Thus, refluxing a mixture of 1,2 g 2-hydrazino-4-phenyl-5-ethyl-6- hydroxypyrimidine and 0.5 g Ac2CH2 in EtOH 3 h gave 99% I (R = Ph, R1 = Et, R2 = OH).

IT 73054-69-0P 73054-70-3P 73054-71-4P
73054-72-5P 73054-74-7P 73054-75-8P
73054-76-9P 73054-77-0P 73054-78-1P
73054-80-5P 73054-81-6P 73054-82-7P
73054-83-8P 73054-84-9P 73054-88-3P
73054-89-4P 73054-90-7P 73054-91-8P
73054-92-9P 73054-93-0P 73054-97-4P
73054-98-5P 73054-99-6P 73055-00-2P
73055-01-3P 73055-02-4P 73055-03-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 73054-69-0 HCAPLUS
CN 2-Propanone, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-5-propyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-70-3 HCAPLUS
CN 2-Propanone, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-hexyl-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-71-4 HCAPLUS
CN 2-Propanone, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-72-5 HCAPLUS
CN 2-Propanone, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5,6-dimethyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-74-7 HCAPLUS
CN Benzaldehyde, 4-chloro-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-75-8 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 73054-76-9 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5,6-dimethyl-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 73054-77-0 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-5-propyl-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 73054-78-1 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-hexyl-6-methyl-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 73054-80-5 HCAPLUS
CN Acetic acid, 2-chloro-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-5-propyl-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 73054-81-6 HCAPLUS
CN Acetic acid, 2-chloro-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-hexyl-6-methyl-4-pyrimidinyl]hydrazide (CA INDEX NAME)



RN 73054-82-7 HCAPLUS
CN Pyrimidine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-hydrazinyl-5,6-dimethyl- (CA INDEX NAME)



RN 73054-83-8 HCAPLUS
CN Pyrimidine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-hydrazinyl-6-methyl-5-propyl- (CA INDEX NAME)



RN 73054-84-9 HCAPLUS
CN Pyrimidine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-hexyl-4-hydrazinyl-6-methyl- (CA INDEX NAME)



RN 73054-88-3 HCAPLUS
CN Formaldehyde, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-89-4 HCAPLUS
CN Acetaldehyde, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-90-7 HCAPLUS
CN Butanal, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-91-8 HCAPLUS
CN Ethanone, 1-phenyl-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-92-9 HCAPLUS
CN Benzaldehyde, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-93-0 HCAPLUS
CN 4(1H)-Pyrimidinone, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-, (diphenylmethylene)hydrazone (9CI) (CA INDEX NAME)



RN 73054-97-4 HCAPLUS
CN Acetaldehyde, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5,6-dimethyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-98-5 HCAPLUS
CN Benzaldehyde, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5,6-dimethyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73054-99-6 HCAPLUS
CN Ethanone, 1-phenyl-, 2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-5,6-dimethyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73055-00-2 HCAPLUS
CN Pyrimidine, 5-butyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-hydrazinyl-6-methyl- (CA INDEX NAME)



RN 73055-01-3 HCAPLUS
CN Acetaldehyde, 2-[5-butyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73055-02-4 HCAPLUS
CN Butanal, 2-[5-butyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



RN 73055-03-5 HCAPLUS
CN 2-Propanone, 2-[5-butyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]hydrazone (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L28 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1979:611359 HCAPLUS Full-text
DOCUMENT NUMBER: 91:211359
ORIGINAL REFERENCE NO.: 91:34061a,34064a
TITLE: Synthesis and antibacterial activity of 6-substituted-2-(3,5-dimethyl-1-pyrazolyl)-4-phenyl- and -4-methylpyrimidines
AUTHOR(S): Nishimura, Tamio; Fujita, Syuji; Tanaka, Akemi; Matsumoto, Kuniomi; Kawakami, Masao; Fukuyasu, Harumi; Fukuyasu, Tsuguaki; Kazuno, Yuzo; Watanabe, Tetsuro
CORPORATE SOURCE: Sch. Hyg. Sci., Kitasato Univ., Sagamihara, Japan
SOURCE: Bokin Bobai (1979), 7(4), T159-T171
CODEN: BOBODP; ISSN: 0385-5201
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI



I

AB Pyrazolylpyrimidines I [R = OH, Cl, SR2 (R2 = Me, Pr, hexyl), NHNH2, NHR3 (R3 = C2-6 alkyl), NH2, OR4 (R4 = Me, Pr, CHMe2), NHNHC(S)NHBu, NHC(S)NHBu, imidazolyl, 3,5-dimethylpyrazolyl, SC(:NH)NH2.HCl, 6-alkyl-4-(3,5-dimethylpyrazol-1-yl)imidazolylthio; R1 = Me, Ph] were prepared The fungicidal activity (min. inhibitory concentration) of some of I against Pyricularia oryzae were 12-50 μg/mL and the bactericidal activity against common gram pos. bacteria were 25-50 μg/mL.

IT 28831-59-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(fungicidal and bactericidal activity of)
RN 28831-59-6 HCAPLUS
CN Pyrimidine, 2,4-bis(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl- (CA INDEX NAME)



IT 71874-90-3P 71874-91-4P 71874-92-5P
71874-93-6P 71874-94-7P 71875-03-1P
71875-05-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and fungicidal and bactericidal activity of)
RN 71874-90-3 HCAPLUS
CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-N-ethyl-6-methyl- (CA INDEX NAME)



RN 71874-91-4 HCAPLUS
CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-N-propyl- (CA INDEX NAME)



RN 71874-92-5 HCAPLUS
CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 71874-93-6 HCAPLUS
CN 4-Pyrimidinamine, N-butyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl- (CA INDEX NAME)



RN 71874-94-7 HCAPLUS
CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-N-hexyl-6-methyl- (CA INDEX NAME)



RN 71875-03-1 HCAPLUS
CN Hydrazinecarbothioamide, N-butyl-2-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 71875-05-3 HCAPLUS
CN Thiourea, N-butyl-N'-[2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-4-pyrimidinyl]- (CA INDEX NAME)



IT 71875-07-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, alkoxylation, and fungicidal and bactericidal activity of)
RN 71875-07-5 HCAPLUS
CN Pyrimidine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-(1H-imidazol-1-yl)-6-methyl- (CA INDEX NAME)



IT 71874-96-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, reaction with isothiocyanate, and fungicidal and bactericidal activity of)
RN 71874-96-9 HCAPLUS
CN 4-Pyrimidinamine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl- (CA INDEX NAME)



IT 65004-45-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, reactions, and fungicidal and bactericidal activity of)
RN 65004-45-7 HCAPLUS
CN Pyrimidine, 2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-hydrazinyl-6-methyl- (CA INDEX NAME)



=> => d stat que l37
L1 STR



VAR G1=CH/10
NODE ATTRIBUTES:
NSPEC IS RC AT 8
NSPEC IS RC AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L3 9002 SEA FILE=REGISTRY SSS FUL L1
L6 STR



NODE ATTRIBUTES:
NSPEC IS C AT 8
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L7 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L8 STR



REP G1=(0-19) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L9 STR



REP G1=(0-19) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L10 STR



VAR G1=11/16/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L11 STR



VAR G1=11/16/22
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE
L13 4967 SEA FILE=REGISTRY SUB=L3 SSS FUL L6 OR L7 OR L8 OR L9 OR L10 OR L11
L14 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L15 4 SEA FILE=REGISTRY SUB=L3 SSS FUL L14
L16 STR



Page 1-A



Page 2-A
VAR G2=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/14
REP G3=(3-10) C
REP G4=(0-19) C
VAR G5=17/22/26/32/41/53
REP G6=(0-5) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 67

STEREO ATTRIBUTES: NONE
L17 1 SEA FILE=REGISTRY SUB=L3 SSS FUL L16
L18 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L15
L19 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L17
L20 322253 SEA FILE=HCAPLUS ABB=ON PLU=ON "ANTIMICROBIAL AGENTS"/CV OR ANTIMICROB? OR DISINFECT? OR ANTISEPT? OR ANTIBACT? OR BACTERICID? OR BACTERIOSTAT? OR ("ANTIBACTERIAL AGENTS"/CV OR "ANTIBACTERIAL AGENTS (L) SYNERGISTIC"/CV OR "ANTIBACTERIOPHAGIC ACTION"/CV OR ANTISEPTICS/CV OR "BACTERICIDAL ACTION"/CV OR "BACTERICIDAL ACTION (L) SYNERGISTIC"/CV OR "BACTERICIDAL ACTION AND BACTERIOSTATIC ACTION"/CV OR "BACTERICIDAL ACTION OR BACTERIOSTATIC ACTION"/CV OR BACTERICIDES/CV OR "BACTERICIDES, DISINFECTANTS AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "BACTERICIDES, DISINFECTANTS, AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS, AND ANTISEPTICS (L) SYNERGISTIC"/CV OR BACTERIOSTASIS/CV OR "DISINFECTANTS AND ANTISEPTICS"/CV OR "DISINFECTANTS AND ANTISEPTICS (L) SYNERGISTIC"/CV OR "MICROBICIDAL AND

```
                MICROBIOSTATIC ACTION (L) BACTERIOSTATIC"/CV OR SPIROCHETICIDES
                /CV) OR GERMICID?
L21           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L18 OR L19) AND L20
L22         738 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L13
L23          23 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L22(L)L20
L24          21 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23 NOT L21
L25        4031 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3 NOT (L13 OR L15 OR L17)
L26         411 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L25
L27          13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L26(L)L20
L28           5 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L27 NOT (L21 OR L24)
L29          24 SEA FILE=HCAPLUS ABB=ON  PLU=ON  ("MARQUAIS BIENEWALD S"/AU OR
                "MARQUAIS BIENEWALD SOPHIE"/AU) OR ("MARQUAIS S"/AU OR
                "MARQUAIS SOPHIE"/AU)
L30          11 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "HOLZL WERNER"/AU
L31          79 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "PREUSS ANDREA"/AU OR
                ("PREUSS A"/AU OR "PREUSS A F"/AU OR "PREUSS A K"/AU OR
                "PREUSS A MICHAEL"/AU OR "PREUSS A W"/AU)
L32           4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  "MEHLIN ANDREAS"/AU
L33           9 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L29 AND (L30 OR L31 OR L32)
L34           0 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L30 AND (L31 OR L32)
L35           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L31 AND L32
L36           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L29 OR L30 OR L31 OR L32)
                AND ((L18 OR L19) OR L22 OR L26)
L37           8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR L36)
                NOT (L21 OR L24 OR L28)


=> d ibib abs hitstr l37 1-8

L37  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:69952  HCAPLUS  Full-text
DOCUMENT NUMBER:          148:169165
TITLE:                    Polysiloxane antimicrobials, their preparation and use
INVENTOR(S):              Marquais-Bienewald, Sophie; Wallquist, Olof;
                          Preuss, Andrea; Elder, Stewart Todd
PATENT ASSIGNEE(S):       Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE:                   PCT Int. Appl., 45 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2008006744         A2    20080117    WO 2007-EP56703         20070704
     WO 2008006744         A3    20080703
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
             MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
             PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
```

BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2658147	A1	20080117	CA 2007-2658147		20070704
EP 2040550	A2	20090401	EP 2007-787025		20070704
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS					
KR 2009031551	A	20090326	KR 2009-700176		20090106
IN 2009CN00232	A	20090605	IN 2009-CN232		20090113
CN 101516198	A	20090826	CN 2007-80034306		20090316
PRIORITY APPLN. INFO.:			EP 2006-117256	A	20060714
			WO 2007-EP56703	W	20070704

AB Oligo- or polysiloxanes, which are characterized by containing ≥3, for example 4-3000, Si atoms in the main chain, and where ≥1 is contained in a moiety of the repeat unit formula R1(R2XR3Y)SiO whose open bond of the O atom is linked to another Si atom of the oligo- or polysiloxane main chain, and whose open bond of the Si atom is linked either to another O atom of the oligo- or polysiloxane main chain or to R'1, where R1 and R'1 = C1-10 alkyl, R2 and R3 = C1-18alkylene, X is a divalent spacer group selected from O, NR4, N(COR'5), CONR'4, OCONR'4; Y = OCOR5, NHCOR5, NHR4, COOR5, CONHR4, NR'4R4; R4 = C6-C18 organic residues containing ≥1 aryl moiety; R'4 = R4 or H, C1-20 alkyl, C7-C20 phenylalkyl, C4-C12cycloalkyl; R5 = R7Z; R'5 = R5 or H, C1-20 alkyl, C7-C20 phenylalkyl, C4-C12cycloalkyl; R7 = C1-C20alkylene, which may be interrupted by phenylene, C4-C12cycloalkylene, O, NR'4 or is unsubstituted or substituted phenylene or C4-C12cycloalkylene; Z = halogen or N+R8R9R10; R8-10 = C1-20 alkyl, C7-C20 phenylalkyl, C4- C12cycloalkyl, unsubstituted or substituted aryl or 2 of R8, R9 and R10 are linked together to form a quaternized aliphatic, substituted or unsubstituted N-heterocyclic ring of 4-6 C atoms such as a piperidine ring; or all of R8-10 are linked together to form, together with the N atom they are bonding to a substituted or unsubstituted N-heterocyclic ring system of 4-7 C atoms.

L37 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:846067 HCAPLUS Full-text
DOCUMENT NUMBER: 147:212809
TITLE: Ethenimine polymer based anti-microbial agents, preparation and uses
INVENTOR(S): Huang, Xinyu; Deisenroth, Ted; Preuss, Andrea; Marquais-Bienewald, Sophie; Jennings, John; Hendricks-Guy, Carmen
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007085552	A2	20070802	WO 2007-EP50420	20070117
WO 2007085552	A3	20080327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,				

	TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW					
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA					
AU 2007209376		A1	20070802	AU 2007-209376		20070117
CA 2636739		A1	20070802	CA 2007-2636739		20070117
EP 1984426		A2	20081029	EP 2007-726199		20070117
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS					
JP 2009524719		T	20090702	JP 2008-551756		20070117
US 20070231291		A1	20071004	US 2007-656863		20070123
KR 2008086520		A	20080925	KR 2008-718170		20080723
IN 2008CN03932		A	20090313	IN 2008-CN3932		20080725
CN 101374885		A	20090225	CN 2007-80003715		20080728
PRIORITY APPLN. INFO.:				US 2006-762808P	P	20060127
				WO 2007-EP50420	W	20070117

GI



I



II

AB Polymeric anti-microbial agents produced by substituting the nitrogen atoms in the backbone of ethenimine polymers are provided. The agents are believed to have low human toxicity while being effective against a variety of pathogens and are useful in applications involving human contact, such as cosmetics, hair care products and textiles, as well as in applications with much less human contact, such as coatings. 10-100% Of the nitrogen atoms of the ethenimine polymer or co-polymer backbone are substituted by one or more substituents. The substituent is a C1-24 alkyl, C3-24 alkenyl, C1-24 alkylcarbonyl or C3-24 alkenylcarbonyl which are uninterrupted or interrupted one or more times by one or more oxygen atoms, sulfur atoms, - SO- or -SO2-, and which are substituted one or more times by one or more moieties C3-6 cycloalkyl, -OR, -COOR, -COOM, -SO3M, -SO3H, phosphonic acid, halogen, -CONR'R, - NR'R, phosphonate salt, ammonium salt or group of the formulas -C(NRR')=NR", -C-NR'''-C(NRR')=NR", -L-Ar-, -CO-L-Ar-, or a group -Si(G)3 wherein each G is independently hydroxyl, C14 alkyl or C14 alkoxy, with the proviso that uninterrupted C1-24 alkyl is not substituted by biguanide, C3-6 cycloalkyl, -COOM, -COOR where R is an unsubstituted alkyl, -OR where R is H or unsubstituted alkylcarbonyl or -CONR'R unless at least one other of the substituents is also present. The substituent can also be a heterocycle of the formulas I or II, wherein Y and Y' are independently N, C-R, C-OR or C-NRR' and D and D' are independently R, -OR -C(NRR')=NR", -C(=NR")-NR-[(CH2)m-NR-C(=NR")-NR-]n-R', -C(=NR")-NR-[C(=NR")-NR-]n-R', wherein m and n independently are 1, 2, 3, 4, 5 or 6; or -L-Poly where Poly is branched or unbranched polymer or oligomer selected from polyether, polysiloxane, styrenic polymer or polyol. R, R' and R", independently of each other are hydrogen; a group -L-Ar, -CO-L-Ar, or -CO-O-L-Ar; C1-24 alkyl, C3-24 alkenyl, C3-6 cycloalkyl or C1-24 alkylcarbonyl which are uninterrupted or interrupted one or more times by one or more oxygen atoms, sulfur atoms, carbonyl, -COO-, -CONH-, -NH-,-CON(C1-8 alkyl)- or -N(C1-8 alkyl)-, which uninterrupted or

interrupted alkyl, alkenyl, cycloalkyl or alkylcarbonyl are unsubstituted or substituted one or more times by one or more halogen, -OH, C7-12 aralkyl, C2-12 alkylcarbonyl, C1-24 alkoxy, C2-24 alkylcarboxy, -COOM, -CONH2, -CON(H)(C1-8 alkyl), -CON(C1-8 alkyl)2, -NH2, -N(H)(C1-8 alkyl), -N(C1-8 alkyl)2, -SO3M, Ph, Ph substituted one or more times by one or more C1_8 alkyl, naphthyl, naphthyl substituted one or more times by one or more C1_8 alkyl, purine, pyridine, pyrimidine, triazine or imidazole which purine, pyridine, pyrimidine, triazine or imidazole are unsubstituted or substituted by one or more C1-12 alkyl wherein the purine, pyridine, pyrimidine, triazine or imidazole is neutral or ionically charged, amidine, guanidine, ammonium salt, phosphonic acid, phosphonate salt or a group -NQ-C(=NQ)-NQQ', wherein each Q or Q' is independently hydrogen, C1-12 alkyl, Ph or benzyl; or when attached to a nitrogen atom, R and R', together with the nitrogen atom to which they are attached, form a 5-, 6- or 7-membered ring which is uninterrupted or interrupted by -O-, -NH- or-N(C1-12 alkyl)-. L is a direct bond, C1-12 alkylene which is uninterrupted or interrupted by one or more oxygen atoms and which is unsubstituted or substituted one or more times by one or more -OH, C1-8 alkyl, C1-24 alkoxy, C2-24 alkylcarboxy, -NH2, -N(H)(C1-8 alkyl), -N(C1-8 alkyl)2 or ammonium salt. Ar is C6-10 aromatic or C1-9 saturated or unsatd. heterocycle which are unsubstituted or substituted one or more times by one or more halogen, -OH, C1-24 alkoxy, C2-24 alkylcarboxy, -COOQ", -CONH2, -CON(H)(C1-8 alkyl), -CON(C1-8 alkyl)2-NH2, -N(H)(C1-8 alkyl), -N(C1-8 alkyl)2, -SO3M, SO3H, ammonium salt, phosphonic acid, phosphonate salt, C1-24 alkyl which is unsubstituted or substituted one or more times by one or more halogen, Ph which is unsubstituted or substituted by one or more times by one or more C1-8 alkyl, naphthyl, purine, pyridine, pyrimidine, triazine or imidazole which purine, pyridine, pyrimidine, triazine or imidazole are unsubstituted or substituted by one or more C1-12 alkyl wherein the purine, pyridine, pyrimidine, triazine or imidazole is neutral or is ionically charged; wherein Q" is hydrogen, metal cation, glycol ether, polysiloxane, Ph or benzyl, or Ph or benzyl substituted one or more times by one or more halogen, hydroxy, C1-24 alkoxy or C1-12 alkyl; M is a metal cation or an ammonium cation and when the N atom of the ethylenimine polymer is tetra substituted, it is a cation with a corresponding counter anion. OS.CITING REF
COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L37 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:520448 HCAPLUS Full-text
TITLE: Recent advances in polymeric antimicrobials
AUTHOR(S): Hendricks-Guy, Carmen; Deisenroth, Ted; Huang, Xinyu; Preuss, Andrea; Marquais-Bienewald, Sophie; Jennings, John
CORPORATE SOURCE: Ciba Specialty Chemicals Corporation, Tarrytown, NY, 10591, USA
SOURCE: Abstracts, 39th Middle Atlantic Regional Meeting of the American Chemical Society, Collegeville, PA, United States, May 16-18 (2007), MARM-019. American Chemical Society: Washington, D. C.
CODEN: 69JFDW
DOCUMENT TYPE: Conference; Meeting Abstract
LANGUAGE: English
AB Polymeric antimicrobials containing biocidal functionality such as biguanide, phosphonium salts, quaternary alkyl ammonium salts and quaternary pyridinium salts are known and provide several advantages over conventional antimicrobials. For example, disinfectant polyhexamethylenebiguanide (PHMB), is a polymeric antimicrobial found to be effective against a wide variety of microbes at low dose levels. Advantages of polymeric antimicrobials may include an increase in efficacy, better substrate compatibility, effective antimicrobial lifetime and reduction in residual human and animal toxicity.

Current areas of investigation include the introduction of antimicrobial functional groups onto polyethyleneimine (PEI). This paper describes synthetic approaches to construct novel PEI functionalized antimicrobials that provide a broad spectrum of activity.

L37 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:120875 HCAPLUS Full-text
DOCUMENT NUMBER: 142:197692
TITLE: Preparation of 3-aryl-2-cyano-3-hydroxy-acrylic acid derivatives as antimicrobials which prevent bacterial adhesion to surfaces
INVENTOR(S): Rele, Dinesh Narendra; Bhatti, Harjinder Singh; Hoelzl, Werner; Marquais-Bienewald, Sophie; Mathias, Errol Vincent; Preuss, Andrea; Wagner, Barbara
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005012235	A1	20050210	WO 2004-EP51533		20040719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
EP 1651177	A1	20060503	EP 2004-742002		20040719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
CN 1829684	A	20060906	CN 2004-80022080		20040719
JP 2007500170	T	20070111	JP 2006-521570		20040719
KR 2006059977	A	20060602	KR 2006-701622		20060124
US 20060228965	A1	20061012	US 2006-565789		20060125
US 7476753	B2	20090113			
MX 2006001069	A	20060731	MX 2006-1069		20060127
IN 2006CN00352	A	20070706	IN 2006-CN352		20060127
PRIORITY APPLN. INFO.:			EP 2003-102324	A	20030729
			WO 2004-EP51533	W	20040719

OTHER SOURCE(S): CASREACT 142:197692; MARPAT 142:197692
GI



AB Title compds. (I, II, III; R1 = H, C1-C20 alkyl, C1-C20 alkoxy, CF3, C6-C10 aryl, Q1; R2 = H, C1-C20 alkyl), were prepared Thus, n-octyl cyanoacetate was stirred with LDA in THF for 15 min. at -78° followed by addition of biphenyl-4-carbonyl chloride in THF followed by stirring for 45 min. to give 23% 3-(biphen-4-yl)-2-cyano-3-hydroxyacrylic acid n-octyl ester. The latter inhibited S. aureus with a min. inhibitory concentration of <3.75 μM.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:354901 HCAPLUS Full-text
DOCUMENT NUMBER: 140:374899
TITLE: Preparation of bis(N-alkylbenzylamine) derivatives as antimicrobial agents
INVENTOR(S): Marquais-Bienewald, Sophie; Hoelzl, Werner; Preuss, Andrea; Mehlin, Andreas; Brunner, Frederic
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035521	A1	20040429	WO 2003-EP11384	20031014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003271727	A1	20040504	AU 2003-271727	20031014
EP 1556335	A1	20050727	EP 2003-753556	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015548	A	20050823	BR 2003-15548	20031014
CN 1705633	A	20051207	CN 2003-80101550	20031014
JP 2006503907	T	20060202	JP 2005-501291	20031014

US 20060052375	A1	20060309	US 2005-531232		20050413
MX 2005004138	A	20050803	MX 2005-4138		20050419
IN 2005CN00994	A	20070615	IN 2005-CN994		20050520
PRIORITY APPLN. INFO.:			EP 2002-405898	A	20021021
			CH 2003-91	A	20030122
			WO 2003-EP11384	W	20031014

OTHER SOURCE(S): MARPAT 140:374899
GI



I

II

AB The title compds. with general formula of I [wherein R1 = H, alkyl, CF3, cycloalkyl, phenylalkyl, phenylalkoxy, alkylaminoalkyl, dialkylaminoalkyl, or alkoxyalkyl, R2 = alkyl, hydroxyalkyl, Ph, phenylalkyl, phenylalkoxy, alkylaminoalkyl, dialkylaminoalkyl, or heteroarylalkyl; or R1 and R2 together form a 5-7 membered ring with the nitrogen atom attached; with provisos] are prepared For example, 4,4'-biphenyldicarboxaldehyde was reacted with 1-octylamine in THF, followed by the addition of NaBH(OAc)3 to give II (84%). I showed strong inhibitory activities against Escherichia coli ATCC 6538 and Staphylococcus aureus ATCC 10536. I are suitable for the antimicrobial treatment of surfaces, especially as antimicrobial active ingredients against gram-pos. and gram-neg. bacteria.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:757654 HCAPLUS Full-text
DOCUMENT NUMBER: 139:276698
TITLE: Preparation benzyl alcohol ethers with antimicrobial activity
INVENTOR(S): Hoelzl, Werner; Koppold, Juergen; Marquais-Bienewald, Sophie; Preuss, Andrea
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003078367	A2	20030925	WO 2003-EP2618	20030313

WO 2003078367 A3 20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003208707 A1 20030929 AU 2003-208707 20030313
EP 1485339 A2 20041215 EP 2003-706613 20030313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005520829 T 20050714 JP 2003-576376 20030313
CN 1642890 A 20050720 CN 2003-806241 20030313
IN 2004CN02045 A 20060224 IN 2004-CN2045 20040914
US 20050124579 A1 20050609 US 2004-507965 20040915
PRIORITY APPLN. INFO.: EP 2002-405210 A 20020319
WO 2003-EP2618 W 20030313

OTHER SOURCE(S): MARPAT 139:276698

AB The preparation (i.e., by the etherification of 4-hydroxybenzaldehyde with 1-bromooctane followed by reduction with lithium aluminumhydride) and use of use of benzyl alc. ethers [e.g., 4-(octyloxy)benzyl alc.] as microbicidal active substances is described. These compds. exhibit a marked effect against pathogenic Gram-pos. and Gram-neg. bacteria and are suitable for antimicrobial treatment, in particular preservation and disinfection, of surfaces.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:757432 HCAPLUS Full-text
DOCUMENT NUMBER: 139:272355
TITLE: 4-aminopyrimidines as antimicrobial agents
INVENTOR(S): Marquais-Bienewald, Sophie; Hoelzl, Werner; Haap, Wolfgang; Preuss, Andrea; Mehlin, Andreas
PATENT ASSIGNEE(S): Ciba Specialty Chemicals Holding Inc., Switz.
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077656	A1	20030925	WO 2003-EP2438	20030310

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003214110	A1	20030929	AU 2003-214110	20030310
EP 1484971	A1	20041215	EP 2003-709767	20030310
EP 1484971	B1	20070704		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005520821	T	20050714	JP 2003-575716	20030310
CN 1642422	A	20050720	CN 2003-805989	20030310
AT 366045	T	20070715	AT 2003-709767	20030310
ES 2290436	T3	20080216	ES 2003-709767	20030310
US 20050143387	A1	20050630	US 2004-507800	20040913
IN 2004CN02294	A	20070223	IN 2004-CN2294	20041011
PRIORITY APPLN. INFO.:			EP 2002-405201 A	20020315
			WO 2003-EP2438 W	20030310

OTHER SOURCE(S): MARPAT 139:272355
GI



I

AB 4-Aminopyrimidines I (Markush included) are prepared as antimicrobial agents.
OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:494677 HCAPLUS Full-text
TITLE: High-throughput techniques. Posters. 11.20. High-throughput screening of antimicrobial agents for cosmetic and household uses - example of use from industrial research
AUTHOR(S): Gampp, K.; Hoffstetter, F.; Petzold, K.; Haap, W.; Marquais-Bienewald, S.; Hoelzl, W.; Preuss, A.; Ochs, D.
CORPORATE SOURCE: Ciba Spezialitaetenchem. Grenzach GmbH, Grenzach-Wyhlen
SOURCE: Chemie Ingenieur Technik (2002), 74(5), 567
CODEN: CITEAH; ISSN: 0009-286X
PUBLISHER: Wiley-VCH Verlag GmbH
DOCUMENT TYPE: Journal; Miscellaneous
LANGUAGE: German
AB Unavailable

```
=> d his nofile

     FILE 'REGISTRY' ENTERED AT 18:43:56 ON 16 SEP 2009
L1             STR
L3          9002 SEA SSS FUL L1
L6             STR
L7             STR
L8             STR
L9             STR
L10            STR
L11            STR
L13         4967 SEA SUB=L3 SSS FUL L6 OR L7 OR L8 OR L9 OR L10 OR L11
L14            STR
L15            4 SEA SUB=L3 SSS FUL L14
L16              STR L14
L17            1 SEA SUB=L3 SSS FUL L16

     FILE 'HCAPLUS' ENTERED AT 19:03:28 ON 16 SEP 2009
L18            4 SEA ABB=ON  PLU=ON  L15
L19            1 SEA ABB=ON  PLU=ON  L17
L20       322253 SEA ABB=ON  PLU=ON  "ANTIMICROBIAL AGENTS"/CV OR ANTIMICROB?
                  OR DISINFECT? OR ANTISEPT? OR ANTIBACT? OR BACTERICID? OR
                  BACTERIOSTAT? OR ("ANTIBACTERIAL AGENTS"/CV OR "ANTIBACTERIAL
                  AGENTS (L) SYNERGISTIC"/CV OR "ANTIBACTERIOPHAGIC ACTION"/CV
                  OR ANTISEPTICS/CV OR "BACTERICIDAL ACTION"/CV OR "BACTERICIDAL
                  ACTION (L) SYNERGISTIC"/CV OR "BACTERICIDAL ACTION AND
                  BACTERIOSTATIC ACTION"/CV OR "BACTERICIDAL ACTION OR BACTERIOST
                  ATIC ACTION"/CV OR BACTERICIDES/CV OR "BACTERICIDES, DISINFECTA
                  NTS AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS AND
                  ANTISEPTICS (L) SYNERGISTIC"/CV OR "BACTERICIDES, DISINFECTANTS
                  , AND ANTISEPTICS"/CV OR "BACTERICIDES, DISINFECTANTS, AND
                  ANTISEPTICS (L) SYNERGISTIC"/CV OR BACTERIOSTASIS/CV OR
                  "DISINFECTANTS AND ANTISEPTICS"/CV OR "DISINFECTANTS AND
                  ANTISEPTICS (L) SYNERGISTIC"/CV OR "MICROBICIDAL AND MICROBIOST
                  ATIC ACTION (L) BACTERIOSTATIC"/CV OR SPIROCHETICIDES/CV) OR
                  GERMICID?
L21            3 SEA ABB=ON  PLU=ON  (L18 OR L19) AND L20
                  D STAT QUE L21
                  D IBIB ABS HITSTR L21 1-3
L22          738 SEA ABB=ON  PLU=ON  L13
L23           23 SEA ABB=ON  PLU=ON  L22(L)L20
L24           21 SEA ABB=ON  PLU=ON  L23 NOT L21
                  D STAT QUE L24
                  D IBIB ABS HITSTR L24 1-21

     FILE 'REGISTRY' ENTERED AT 19:05:38 ON 16 SEP 2009
L25         4031 SEA ABB=ON  PLU=ON  L3 NOT (L13 OR L15 OR L17)

     FILE 'HCAPLUS' ENTERED AT 19:05:51 ON 16 SEP 2009
L26          411 SEA ABB=ON  PLU=ON  L25
L27           13 SEA ABB=ON  PLU=ON  L26(L)L20
L28            5 SEA ABB=ON  PLU=ON  L27 NOT (L21 OR L24)
                  D STAT QUE L28
                  D IBIB ABS HITSTR L28 1-5
L29           24 SEA ABB=ON  PLU=ON  ("MARQUAIS BIENEWALD S"/AU OR "MARQUAIS
                  BIENEWALD SOPHIE"/AU) OR ("MARQUAIS S"/AU OR "MARQUAIS
                  SOPHIE"/AU)
L30           11 SEA ABB=ON  PLU=ON  "HOLZL WERNER"/AU
```

```
L31          79 SEA ABB=ON  PLU=ON  "PREUSS ANDREA"/AU OR ("PREUSS A"/AU OR
                "PREUSS A F"/AU OR "PREUSS A K"/AU OR "PREUSS A MICHAEL"/AU OR
                "PREUSS A W"/AU)
L32           4 SEA ABB=ON  PLU=ON  "MEHLIN ANDREAS"/AU
L33           9 SEA ABB=ON  PLU=ON  L29 AND (L30 OR L31 OR L32)
L34           0 SEA ABB=ON  PLU=ON  L30 AND (L31 OR L32)
L35           3 SEA ABB=ON  PLU=ON  L31 AND L32
L36           1 SEA ABB=ON  PLU=ON  (L29 OR L30 OR L31 OR L32) AND ((L18 OR
                L19) OR L22 OR L26)
L37           8 SEA ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR L36) NOT (L21 OR L24
                OR L28)
                D STAT QUE L37
                D IBIB ABS HITSTR L37 1-8

=>
```